Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement

Johan F. K. F. Ilvemark, Tawnya Hansen, Thomas M. Goodsall, Jakob B. Seidelin, Heba Al-Farhan, Mariangela Allocca, Jakob Begun, Robert V. Bryant, Dan Carter, Britt Christensen, Marla C. Dubinsky, Krisztina B. Gecse, Torsten Kucharzik, Cathy Lu, Christian Maaser, Giovanni Maconi, Kim Nylund, Carla Palmela, Stephanie R. Wilson, Kerri Novak, Rune Wilkens, on behalf of the International Bowel Ultrasound [IBUS] Group

Abstract

Background and Aims: No consensus exists on defining intestinal ultrasound response, transmural healing, or transmural remission in inflammatory bowel disease, nor clear guidance for optimal...
timings of assessment during treatment. This systematic review and expert consensus study aimed to define such recommendations, along with key parameters included in response reporting.

**Methods:** Electronic databases were searched from inception to July 26, 2021, using pre-defined terms. Studies were eligible if at least two intestinal ultrasound (IUS) assessments at different time points during treatment were reported, along with an appropriate reference standard. The QUADAS-2 tool was used to examine study-level risk of bias. An international panel of experts \( n = 18 \) rated an initial 196 statements [RAND/UCLA process, scale 1–9]. Two videoconferences were conducted, resulting in additional ratings of 149 and 13 statements, respectively.

**Results:** Out of 5826 records, 31 full-text articles, 16 abstracts, and one research letter were included; 83% [40/48] of included studies showed a low concern of applicability, and 96% [46/48] had a high risk of bias. A consensus was reached on 41 statements, with clear definitions of IUS treatment response, transmural healing, transmural remission, timing of assessment, and general considerations when using intestinal ultrasound in inflammatory bowel disease.

**Conclusions:** Response criteria and time points of response assessment varied between studies, complicating direct comparison of parameter changes and their relation to treatment outcomes. To ensure a unified approach in routine care and clinical trials, we provide recommendations and definitions for key parameters for intestinal ultrasound response, to incorporate into future prospective studies.

**Key Words:** Intestinal ultrasound; inflammatory bowel disease; treatment response; transmural remission; transmural healing

1. **Introduction**

Transabdominal intestinal ultrasound (IUS) is gaining acceptance as a point-of-care test to objectively assess disease activity in inflammatory bowel disease (IBD).\(^1\) IUS has several advantages over conventional cross-sectional imaging modalities: it is non-invasive, patient-friendly, easily repeated while being preparation and radiation free. Thus, the clinician can directly assess inflammatory activity in real time, helping patients understand their disease while facilitating clinical decisions without delay.\(^2,3\)

IUS’s ability to assess colonic and small bowel inflammation has been compared with clinical scores, biologic markers, endoscopy, and radiological modalities at diagnosis and during disease flare, with good accuracy in ulcerative colitis [UC]\(^4\) and Crohn’s disease [CD].\(^5\) However, the role of IUS as a monitoring tool after treatment initiation has not been standardised.\(^6,7\) Currently, no consensus definition exists for IUS response or transmural remission/healing [TR], nor clear guidance for optimal assessment intervals during follow-up.\(^8,9\) These standards are vital for the consistent application of IUS as a modality to assess treatment outcomes and establish therapeutic targets, to ensure comparability between future studies.

We aimed to provide expert recommendations for IUS assessment of treatment response in IBD and define IUS key parameters to include in response reporting. We therefore conducted a systematic review of the literature, followed by a RAND/UCLA [University of California at Los Angeles] expert panel appropriateness process.\(^10\)

2. **Materials And Methods**

2.1. **Information sources and searches**

The systematic review was conducted in accordance with the PRISMA recommendations [PROSPERO-ID CRD42019136983]. A systematic search of Embase [Ovid, 1984], Medline [Ovid, 1946], and Cochrane Central from database inception to February 27, 2020, laid the foundation for the expert consensus process. After the consensus process, an additional systematic search on Embase [Ovid, 1984], Medline [Ovid, 1946], and Cochrane Central from February 27, 2020, to July 26, 2021, was performed. The detailed search strategies and the outcomes of interest, eligibility, and exclusion criteria are outlined in Supplementary Material 1, available as Supplementary data at ECCO-JCC online. In the tables and figures, updated search articles are identified by a light grey background.

2.2. **Study selection and data extraction**

All studies were uploaded to the Covidence systematic review software, with automatic removal of duplicates.\(^11\) Using a priori defined eligibility criteria, two researchers screened all uploaded titles and abstracts independently. Studies were eligible for inclusion if patients were diagnosed with IBD, in all disease stages, receiving any pharmacological treatment. Patients should undergo at least two IUS assessments during the study period and disease activity should be assessed by either clinical scores, biochemistry, faecal calprotectin [FC], endoscopy, other cross-sectional imaging, or a combination of the above. When published in peer-reviewed journals/presented at conferences, prospective and retrospective full-text articles and abstracts of international conferences were included. Titles and abstracts that met the eligibility criteria and studies with uncertain eligibility were included for full-text screening. The same two researchers independently reviewed these full-text studies to verify the in- and exclusion criteria. Reference lists from reviews and scoring studies were screened for eligibility before exclusion. Articles reporting on the performance of IUS scores were excluded since the performance of these scores has been evaluated elsewhere.\(^7,12\) In case of disagreement of eligibility, a third researcher was consulted, and consensus through discussion was obtained. During the inclusion process, researchers were not blinded to journal titles, study authors, or institutions. If missing or incomplete data were crucial for the eligibility assessments, study authors were contacted [maximum one email attempt]. All included studies were extracted in accordance with the study protocol. A meta-analysis was not planned, given the expected heterogeneity among studies. The data underlying this article will be shared at reasonable request to the corresponding author.
2.3. Quality assessment

All included studies were independently assessed for risk of bias by at least two researchers, according to the QUADAS-2 tool. Risk of bias was evaluated across four domains: patient selection, index test, reference standard, and flow and timing. Applicability concerns were evaluated across three domains: patient selection, index test, and reference standard. Any disagreements were first handled between two researchers. A third researcher was consulted if a consensus could not be reached.

2.4. RAND/UCLA process

An expert panel consisting of 18 international IUS experts, all active researchers within IBD and IUS, participated in the modified RAND/UCLA process. Experts were selected from the International Bowel Ultrasound (IBUS) group’s executive or scientific committees or close collaborators and active researchers within the topic of this review. There were 195 statements generated based on the evidence from the systematic review, along with additional general statements not covered by the literature search. The expert panelists were asked to individually score the appropriateness of each statement on a Likert scale from 1 [highly inappropriate] to 9 [highly appropriate]. An agreement was met when four or more panelists rated outside the 3-point region containing the median [1–3, 4–6, and 7–9] using the survey tool in REDCap. Dependent on the area of expertise, experts did not vote on all statements [total vote count ranging from 14 to 18, see Supplementary Material 2, available as Supplementary data at ECCO-JCC online]. In particular, some statements on ulcerative colitis (UC) received fewer votes, which reflects the individual panel members’ unwillingness to make a statement based on the low number and quality of published UC articles. Based on the first voting round, the panel met in June 2020 to discuss the voting results via an online videoconference, which led to rephrasing and adding statements for clarification, followed by the second round of individual online rating of 149 statements. A final online videoconference was held to clarify the remaining uncertainties and contradictions in November 2020. A closing voting round with 13 statements followed shortly thereafter.

3. Results

3.1. Systematic review

The first part of the systematic review [database inception to February 27, 2020] resulted in 5419 identified records; 25 articles, 13 abstracts, and one research letter passed the eligibility criteria [Figure 1, white background]. Corresponding authors for three additional articles and five abstracts were contacted for vital data; none rendered any response, which reflects the individual panel members’ unwillingness to make a statement based on the low number and quality of published UC articles. Based on the first voting round, the panel met in June 2020 to discuss the voting results via an online videoconference, which led to rephrasing and adding statements for clarification, followed by the second round of individual online rating of 149 statements. A final online videoconference was held to clarify the remaining uncertainties and contradictions in November 2020. A closing voting round with 13 statements followed shortly thereafter.

3.2. Rand/UCLA process

The results from the RAND/UCLA process [Table 3] are presented together with the results from the systematic review, most recent published data, and expert opinion. The RAND/UCLA statements during all three votes can be viewed in Supplementary Material 2. Under inappropriate [InA], uncertain [Unc], and appropriate [App], the number of panelists voting as either 1–3, 4–6, or 7–9 is presented.

3.3. Statements for both Crohn’s disease and ulcerative colitis

3.3.1. Machine recommendations.

3.3.1.1. Treatment response can be assessed by intestinal ultrasound. [InA. 0, Unc. 0, App. 17]

3.3.1.2. Response should be assessed with:

3.3.1.2.1. the same type of probe [high frequency vs abdominal probe]; [InA. 0, Unc. 2, App. 15]

3.3.1.2.2. constant machine settings [Doppler scale, presets, etc.]; [InA. 1, Unc. 1, App. 15]

A mid- to high-frequency ultrasound probe, >5 MHz, gives higher resolution when imaging the intestine and should therefore be used when assessing inflammation, treatment response, and remission. An abdominal probe may be useful to map out deeper pelvic structures or complications, but lower-frequency probes do not exhibit sufficient resolution for assessing mural inflammation. Consistent machine settings using the same type of probe during all IUS examinations reduce confounding factors, ensuring that changes in IUS are attributable to alteration in pathophysiology rather than equipment/acquisition settings. Although consensus was not achieved, using the same machine during follow-up might be preferable, certainly when assessing colour Doppler signals [CDS] [Supplementary Material 2; second round voting results, 1.2].

3.3.2. Response rate.

3.3.2.1. Response rate detected by intestinal ultrasound is comparable with:

3.3.2.1.1. rate of improvement in luminal inflammation, assessed by endoscopy; [InA. 0, Unc. 3, App. 14]

3.3.2.1.2. rate of magnetic resonance enterography improvement. [InA. 0, Unc. 0, App. 17]
Therapeutic response rates in IBD are at least in part influenced by the individual therapeutic mechanisms of action, compared with placebo response and the severity and chronicity of disease. Response rates also vary depending on the measure, whether clinical, endoscopic, or a radiological modality. These factors make inter-modality comparisons challenging. Nevertheless, published data support IUS findings demonstrating response rates comparable to those seen on endoscopy and magnetic resonance enterography [MRE]. The largest CD IUS trial by Kucharzik et al. \(n=234\) showed that 75% of patients exhibited increased bowel wall thickness [BWT] in the terminal ileum and 47% in the sigmoid colon at baseline. After 12 months of therapy, the rates were reduced to 36% and 23%, respectively \(n=134\).\(^{20}\) In UC, Maaser et al. \(n=224\) showed that 89% exhibited increased BWT in the sigmoid colon at baseline, followed by 38% at Week 12 \(n=178\).\(^{40}\) Similar rates of improvement are reported for endoscopy by Bouguen et al.\(^ {41}\) and Vasudevan et al.\(^ {13}\) and for MRE by Ordás et al.\(^ {14}\) and Castiglione et al.\(^ {19}\)

Regardless of the reference standard, response rates in IBD are drug dependent.\(^ {9}\) IUS accurately reflects this during follow-up. No study specifically reports data on 5-ASA-treated patients, IUS demonstrates a rapid response to steroids. In CD patients, early changes are seen after 3–8 days, with an increasing likelihood of observed change after 4 weeks.\(^ {22}\) In UC, IUS response can be detected after
| Author       | No. of patients | Treatment | Time point of assessment | Reference standard | IUS response/remission definition | BWT decrease or no. of patients with/without increased BWT | CDS decrease or no. of patients with/without increased CDS | IUS remission | IUS response/remission association with reference standard |
|--------------|-----------------|-----------|--------------------------|--------------------|----------------------------------|---------------------------------------------------------|-----------------------------------------------------------|---------------|----------------------------------------------------------|
| Paredes 2019 | 33              | Anti-TNF  | Baseline, 12 weeks, 1 year | CDAI               | Response: decrease in BWT > 2 mm and CDS decrease by 1 grade. Remission: BWT ≤ 3 mm and CDS grade 0 or 1 | Week 12: Median decrease 1.5 mm [24%] | Baseline: CDS 2 or 3: 28 [85%] Week 12: 11 [33%], p < 0.001 | Week 12: 7 [21%], 1 year: 14 [42%] | N/A |
| Paredes 2010 | 24              | Anti-TNF  | Baseline, 2 weeks after induction | CDAI               | Response: BWT decrease > 0.5 mm and CDS decrease by 1 grade. Remission: BWT ≤ 3 mm, CDS grade 0, no intraabdominal complications | Decrease in 11 [46%] patients. Responders [mean ± SD]: 1.2 ± 1.6 mm [19%]. Non-responders: 0.1 ± 0.2 mm, p = 0.01 | Baseline: CDS 2 or 3: 17 [71%] 2 weeks after induction: 11 [46%] p < 0.02, CDS decreased in 10 [42%] | BWT normalisation: 29%, CDS normalisation: 33%, Transmural complications: 50% | No decrease of BWT or CDS in patients without treatment response, p < 0.05 |
| Castiglione 2013 | 133         | Anti-TNF or AZA/6-MP | Baseline, 2 years | CDAI, SES-CD, CRP | Response: N/A. Remission: BWT < 3 mm | Mean decrease anti-TNF: 2.0 mm [33%], AZA/6-MP: 0.4 mm [6%] | N/A | Anti-TNF: 17/66 [25%], AZA/6-MP: 3/67 [5%] |
| Castiglione 2017 | 40           | Anti-TNF  | Baseline, 2 years | CDAI, SES-CD, MRE | Response: N/A. Remission: BWT ≤ 3 mm | Mean decrease IUS: 2.2 mm [36%], MRE: 2.7 mm [N/A] | N/A | Anti-TNF did not determine a significant difference in TR outcome |
Kucharzik 2017<sup>20</sup> | 234 | CS, anti-TNF, AZA/MTX, 5-ASA | Baseline, 3 months, 6 months, and 12 months | HBI | Abnormal BWT TI: >2 mm. Colon: >3 mm. Response: N/A. Remission: N/A | Sub-group 1 [all scans, N = 134]: abnormal BWT at baseline, 3, 6, and 12 months: TI: 75%, 57%, 44%, and 36%, Sigmoid: 47%, 22%, 27%, 23%. All with p-values <0.05. Sub-group 2 [baseline, 3 months, N = 182] TI normalisation: 107 [59%]. A 10% or 25% BWT reduction was found in 95% and 80% of patients, respectively | Sub-group 1: CDS 3 + 4. Baseline, 3, 6, and 12 months: 44%, 18%, 14%, and 10%, p <0.001 | N/A | N/A | Sub-group 2: BWT reduction = HBI reduction in 86%. CDS change [3 + 4 = >1 + 2] correlated with CRP at Months 3 and 12 in both sub-groups. Sub-group 2: correlation between CRP and BWT [TI], Spearman = 0.46 and BWT and HBI [transverse colon], Spearman 0.42

Ripolles 2016<sup>63</sup> | 51 | Anti-TNF, Anti-TNF + AZA/MTX | Baseline, 12 weeks, 1 year, 2 years [clinical] | HBI, CRP | Response: decrease in BWT [≥2 mm], CDS [≥1], CEUS—mural enhancement [≥20%] and/or absence of complications. Remission: BWT ≤3 mm, CDS = 0, no complications | 12 weeks mean decrease: 1.2 mm [18%], p <0.05. 52 weeks: 1.5 mm [24%], p = NS | Baseline CDS 3–4: 43 [84%]. 12 weeks: 19 [37%] p = 0.0001. 52 weeks: 19 [37%] p = NS.26 [51%] improved with normalisation in 7 | N/A | N/A | N/A

Ripolles 2008<sup>88</sup> | 28 | 5-ASA or CS ± AZA | Baseline, 3–8 days, 4 weeks | CDAI, CRP | BWT ≥a 3 mm abnormal. Response: decrease in CDS [3 = ≥2 or 2 = ≥0/1, not from 1 = ≥0] and BWT [≥25% decrease]. Sonographic active disease: CDS ≥2 or BWT >5 mm | 4 weeks mean decrease 0.8 mm [12%], p = NS | Baseline: grade 2–5 vascularity: 18/22 [82%]. CDAI >150 and 46 [67%]. CDAI <150 2nd examination: improvement | N/A | No correlation between clinical and sonographic changes between baseline, 2nd and 3rd examination
| Author         | No. of patients | Treatment | Time point of assessment | Reference standard | IUS response/remission definition | BWT decrease or no. of patients with/without increased BWT | CDS decrease or no. of patients with/without increased CDS | IUS remission | IUS response/remission association with reference standard |
|----------------|----------------|-----------|--------------------------|--------------------|----------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------|----------------------------------------------------------|
| Dubbins 1984  | 19             | AZA/MTX   | Baseline, 2–4 months     | N/A                | N/A                              | Mean decrease 6 mm [60%]                                  | N/A                                                      | N/A           | N/A                                                      |
| Onali 2010    | 2.5            | 5-ASA ± CS | 1 year, 2 years, 3 years | CDAI, Rutgeerts’ score, SBFT | CD recurrence: 1 [BWT >3 mm, 2] stiff loop = increased BWT, not distended by oral contrast. 3] small bowel dilation, diameter >2.5 cm | Mean decrease 6 mm [60%]                                  | 1-year recurrence: 23/25 [100%]; BWT median [range] 5 mm [35–10]. 3.5 mm in one patient with Rutgeerts’ i0. 2 years: 21.21 [100%]. 3 years: 15/15 [100%]. 3.5 mm in one patient with Rutgeerts’ i0 | N/A           | N/A                                                      |
| Moreno 2014   | 30             | Anti-TNF ± AZA/6-MP | Baseline, 14 months [range: 13–25 months] | CDEIS | Remission: BWT ≤3 mm, CDS = 0–1, and CEUS peak enhancement <46% | Baseline CDS 3–4: 27 [90%]. After treatment: 6 [20%], p ≤0.001 | Segmental assessment: 3/59 [64%]. Overall assessment: 15/30 [50%] | Baseline CDS 3–4: 27 [90%]. After treatment: 6 [20%], p ≤0.001 | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] |
| Orlando 2018  | 30             | Anti-TNF  | Baseline, 14 weeks, 52 weeks | Surgery is outcome | Remission: BWT ≤3 mm | Mean SD decrease 0.74 ± 1.2 mm [1.25 ± 1.95%], p ≤0.05. ADA vs. IFX = NS | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] |
| Socaciu 2015  | 13             | N/A       | Baseline, 12 weeks       | CDAI               | N/A                              | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] | Segmental: association: TR vs. ER: [κ = 0.76; p <0.001]. BWT ≤3 mm predicts ER [93%]. Overall: TR vs. ER: [κ = 0.73, p <0.001] BWT ≤3 mm predicts ER [96%] |

**Table 1.** Continued
### Table 1. Continued

| Author         | No. of patients | Treatment | Time point of assessment | Reference standard | IUS response/remission definition | BWT decrease or no. of patients with/without increased BWT | CDS decrease or no. of patients with/without increased CDS | IUS remission | IUS response/remission association with reference standard |
|----------------|----------------|-----------|--------------------------|--------------------|----------------------------------|-----------------------------------------------------------|----------------------------------------------------------|---------------|----------------------------------------------------------|
| Goertz 2018<sup>38, 39</sup> | 11 VED         | Baseline, 2 weeks, 6 weeks, 14 weeks | HBI              | N/A                | 5 responders: baseline: 5.3 ± 0.8 mm. Week 14: 5.3 ± 1.8 mm. 6 non-responders: baseline: 6.6 ± 0.6 mm. 14 weeks 6.1 ± 1.2 mm | 5 responders: baseline: 2.4 ± 0.9. Week 1.4: 1.2 ± 0.8. 6 non-responders: baseline: 2.0 ± 0.6. 14 weeks 1.5 ± 0.8 | N/A | N/A |
| Quasia 2019<sup>40</sup> | 115 Anti-TNF ± CS | Baseline, 6 to 18 weeks | CDIA, CDEIS | N/A | 12 weeks decrease: response group: 3.0 mm [43%]. Non-response group: 1.0 mm [14%] | 12 weeks decrease: response group: 3.0 mm [43%]. Non-response group: 1.0 mm [14%] | N/A | N/A |
| Saevik 2014<sup>41</sup> | 14 CS or anti-TNF | Baseline, 1 month, 3 months, 12 months | CDAI              | BWT > 2 mm abnormal if lumen > 0.5 cm or abnormal if BWT > 3 mm + lumen < 0.5 cm | 1-month decrease: 0.3 mm [5%]. 12 weeks: 0.01 mm [0.2%]. 1 year: 1.6 mm [34%] | N/A | N/A |
| Chen 2018<sup>42</sup> | 29 AZA + EEN   | Baseline and when clinical parameters became normal | CDIA, SES-CD | Remission: ≤3 mm and normalisation of IUS parameters: 3/4: positive | Decrease 4.4 mm [47%], p < 0.05 | Positive baseline: 90%. During follow-up: 17%, p < 0.05 | N/A | N/A |
| Hoffman 2019<sup>43</sup> | 57 UST         | Baseline, 24 ± 6 weeks, 24–48 ± 6 weeks | HBI               | Response: ≤3 mm | Baseline abnormal BWT: 19/22 [79%]. 24 ± 6 weeks, 8/13 steroid free clinical remission/response vs. 5/13 non-response. 6/13 [46%] had BWT > 3 mm, p = 0.43. Weeks 24–48 ± 6: 6/13 in response/remission with improvement or no inflammation vs. 5/13 non-response, p = NS | N/A | N/A |
| Author         | No. of patients | Treatment       | Time point of assessment | Reference standard | IUS response/remission definition | BWT decrease or no. of patients with/without increased BWT | CDS decrease or no. of patients with/without increased CDS | IUS remission | IUS response/remission association with reference standard |
|---------------|-----------------|-----------------|--------------------------|--------------------|-----------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------|----------------------------------------------------------|
| Zorzi 2019<sup>33</sup> | 80              | Anti-TNF        | Baseline, 18 months [median] | ER                | BWT: >3 mm, abnormal. Improved lesions: [a] BWT improvement ≥1 mm or normalisation TI <3 mm; colon <4 mm; [b] decreased length; [c] no worsening of other IUS parameters<sup>e</sup> | 41 [51%] were classified as responders, 27 [34%] as partial responders, and 12 [15%] as non-responders. There was a significant relationship between ultrasonographic response and clinical outcomes considered | N/A | N/A | N/A |
| Calabrese 2021<sup>34</sup> | 188             | ADA, IFX, UST, VED | Baseline, 3 months, 6 months, 12 months | HBI, CRP, FCP | Remission: ileum BWT ≤3 mm, colon BWT ≤4 mm and normalisation of other parameters<sup>e</sup> | Ileum: median decrease 3 months: 0.5 mm [8%], 6 months: 1 mm [17%], 12 months: 1 mm [17%], p <0.05, Colon: 3 months: 0.85 mm [14%], 6 months: 1.45 mm [23%], 12 months: 2.35 mm [37%], p <0.05 | Ileum: baseline: 12/158 [79%] with increased CDS. 3 months: 89/158 [56%]. 6 months: 67/156 [43%], 12 months: 52/156 [33%], p <0.05, Colon: baseline: 22/30 [73%], 3 months: 14/30 [47%], 6 months: 10/25 [40%]. 12 months: 9/23 [39%], p <0.05 | 3 months: 31/188 [16%], 6 months: 42/171 [25%]. 12 months: 43/156 [28%] [ADA 27%, IFX 37%, VED 27%, UST 20%] | N/A |
| Hoffman 2020<sup>35</sup> | 23              | UST             | Baseline, 8 weeks       | CDI, CRP          | Response: decrease of BWT ≥1.0 mm | 10/23 [43%] responded | 3 months: 20/30 [67%] | N/A | Responders: substantial decrease in CDAI ≥70 points and CRP ≥0.5 mg/dl in 9/10 and 8/10, respectively |

<sup>Table 1. Continued</sup>
| Author      | No. of patients | Treatment | Time point of assessment | Reference standard | IUS response/remission definition | BWT decrease or no. of patients with/without increased BWT | CDS decrease or no. of patients with/without increased CDS | IUS remission | IUS response/remission association with reference standard |
|------------|----------------|-----------|--------------------------|-------------------|----------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------|----------------------------------------------------------|
| Li Ma 2021 | 77             | AZA/MTX ± Anti-TNF, 5-ASA | Baseline, 6 months      | CDAI, CRP, SES-CD, CTE, MRE | Remission: BWT ≤ 3 mm and normalisation of other parameters<sup>a</sup> | N/A                                                      | N/A                                                      | 6 months: 2.5/77 [32%] | TR and ER poorly correlated, k = 0.387, p < 0.005 |
| Helwig 2021 | 180            | AZA/MTX ± anti-TNF, anti-integrin, systemic CS | Baseline, 12 ± 4 weeks, 52 ± 4 weeks | HBI | Response: BWT reduction > 25% or a normalisation of BWT. Remission: three different definitions. 1) Normalisation of BWT [ileum ≤ 2 mm, sigmoid ≤ 4 mm, rest of colon ≤ 3 mm] and normalised CDS. 2) Normalised BWT and CDS, restored BWS and no I-fat [minus one factor that could not be assessed]. 3) All factors normalised | 12 weeks: No. of patients with response: 77/180 [65%] | N/A                                                      | 12 weeks: Definition: 1: 58/180 [32%] 2: 67/180 [37%] 3: 43/180 [24%] | N/A                                                      |
| Jesen 2020  | 21             | IFX       | Baseline, Week 6         | HBI, partial Mayo score | N/A                                                            | N/A                                                      | Data not stratified by disease. Responders: median 1 CDS point decrease. Non-responders: median 0 CDS points decrease | N/A                                                      | N/A                                                      |

5-ASA, mesalazine; ADA, adalimumab; anti-TNF, infliximab and adalimumab; AZA, azathioprine; AZA/6-MP, azathioprine/mercaptopurine; AZA/MTX, azathioprine/methotrexate; BWS, bowel wall stratification; BWT, bowel wall thickness; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CDS, colour Doppler signal; CRP, C-reactive protein; CS, corticosteroids; CTE, computer tomography enterography; EEN, Total Protein Enteral Nutritional Powder; ER, endoscopic remission; FCP, faecal calprotectin; HBI, Harvey-Bradshaw Index; IFX, infliximab; IUS, intestinal ultrasound; MRE, magnetic resonance enterography; N/A, not available; NS, not significant; UST, ustekinumab; SBFT, small bowel follow-through; SD, standard deviation; SES-CD, Simple Endoscopic Score—Crohn’s Disease; TI, terminal ileum; TR, transmural remission; UC, ulcerative colitis; VED, vedolizumab; CEUS, contrast-enhanced ultrasound.

<sup>a</sup>No colour Doppler signal, normal five-layer bowel wall stratification, no inflammatory fat, no lymph node enlargement, or presence of strictures or pre-stenotic dilation.

<sup>b</sup>No colour Doppler signal, normal bowel wall stratification, no pre-stenotic dilations, strictures, fistulae, inflammatory fat, abscesses, lymphadenopathy, or ascites.

<sup>c</sup>Or fistulising disease.

<sup>d</sup>Colour Doppler signals, length of disease, bowel wall stratification, inflammatory mesenteric fat, lymph nodes, stenosis, pre-stenotic dilation, abscess, fissures, and fistulæ.

<sup>e</sup>Colour Doppler signals, bowel wall stratification, inflammatory mesenteric fat, abscesses, and fistulae.

<sup>f</sup>Report data on both Crohn’s disease and ulcerative colitis, stratified by disease.

<sup>g</sup>Report data on both Crohn’s disease and ulcerative colitis, not stratified by disease.
| Author          | Total no. patients | Treatment          | Time of assessment | Reference standard | IUS response/remission definition | BWT decrease or no. of patients with/without increased BWT | CDS decrease or number of patients with/without increased CDS | IUS remission | IUS response/remission association with reference standard |
|-----------------|--------------------|--------------------|--------------------|--------------------|-----------------------------------|-----------------------------------------------------------|---------------------------------------------------------------|---------------|----------------------------------------------------------|
| Socaciu 2015   | 25                 | N/A                | Baseline, 3 months | Truelove-Witts     | N/A                               | Median decrease 0.15 mm [3%]                              | N/A            | N/A                                                      | Wilcoxon [Z = 0.85, p = NS], Spearman: [rho = 0.28 p = NS] |
| Goertz 2018    | 7                  | VEDO               | Baseline, 2 weeks, 6 weeks, 14 weeks | Mayo score         | N/A                               | Responders: N = 4, 10 mm [17%]. Non-responders: N = 3, NS | N/A            | N/A                                                      |                                                           |
| Parente 2010   | 74                 | CS                 | Baseline, 3 months, 9 months, 15 months | Baron endoscopic score | US severity [0–3] Grade 0 = BWT <4 mm, CDS 0–1 Grade 1 = BWT 4–6 mm, CDS ≥2 Grade 2 = BWT 6–8 mm, CDS ≥2 Grade 3 = BWT >8 mm, CDS ≥2 | Increased BWT: sigmoid colon ≤4.0 mm, descending, transverse and ascending colon ≤3.0 mm | Improvements in CDS: sigmoid colon at baseline, 2, 6, and 12 weeks 23%, 16%, and 13%. Descending colon at baseline, 2, 6, and 12 weeks 83%, 43%, 43%, and 38% | N/A            | 3 months: \( \kappa = 0.76 \) 9 months: \( \kappa = 0.88 \) 15 months: \( \kappa = 0.9 \) N/A |
| Maaser 2019    | 224                | CS, AZA/6-MP, Anti-TNF, Anti-integrin | Baseline, 2 weeks, 6 weeks, 12 weeks | SCCAI              | N/A                               | N/A                                                        | N/A            | N/A                                                      |                                                           |
| Maconi 1999    | 30                 | CS ± 5-ASA ± salazopyrine | Baseline, 2 months | Truelove-Witts X-ray double-contrast barium enema | Abnormal BWT ≥4 mm | 2 months: 16 [53%] improved. Decrease of 2.3 mm [31%]. 14 [47%] did not improve +0.7 mm, \( p = NS \) | N/A            | N/A                                                      | N/A                                                      |
| Yoshida 2011   | 26                 | Cytapheresis ± CS + 5-ASA | Baseline, 2–3 weeks | UC-DAI score, at baseline and 12 months | Early ultrasonic response [EUR]: decrease in BWT by ≥2.3 mm | N/A                                                        | N/A            | 1-year relapse: 1 in EUR group, 9 in non-EUR group      | N/A                                                      |
| Hean 2019      | 9                  | N/A                | Base-line + 11 months [mean] | N/A                | N/A                               | BWT improvement: sonographic remission 1.6 mm, \( p = 0.04 \). No sonographic remission 0.1 mm, \( p = NS \) | N/A            | N/A                                                      | N/A                                                      |
| Author       | Total no. patients | Treatment               | Time of assessment | Reference standard | IUS response/remission definition                                                                 | BWT decrease or no. of patients with/without increased BWT | CDS decrease or number of patients with/without increased CDS | IUS remission | IUS response/remission association with reference standard |
|-------------|--------------------|-------------------------|--------------------|--------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------|-------------------------------------------------------------|---------------|----------------------------------------------------------|
| Maaser 2019 | 65/224 [29%] from study nr 4 | Anti-TNF                | Baseline, 2 weeks, 6 weeks, 12 weeks | SCCAI, CRP, FCP   | Abnormal BWT sigmoid colon, >4 mm, descending colon >3 mm                                                                                             | Week 6: 44 received anti-TNF to [48%] normalised.15 [34%] decrease in BWT | Increased CDS at Weeks 6 and 12 had higher SCCAI than no CDS [p <0.001] | N/A           | N/A                                                     |
| Arienti 1996 | 57                 | High doses of IV CS     | Baseline, 10 days  | Truelove-Witts     | Normal BWT <3 mm “ultrasonic activity index” = the sum of maximum BWT in all four segments [in mm]                                                  | IUS activity in the severe group. All: before treatment: 1.89 mm, after treatment 1.49 mm, p = 0.001. Non-operated: before 1.84 mm, after 1.27 mm, p = <0.001. Operated: before 197 mm, after 184, p = NS US activity in the moderate group. All: before 1.02 mm, after 6.3 mm, p = <0.001. Non-operated: before: 9.9 mm, after 5.6 mm, p = <0.001. Operated: before: 1.20, after 1.10 ± 1.1, NS | N/A           | N/A                                                     |
| De Voogd 2021 | 29                 | TOF                     | Baseline, 8 weeks  | Endoscopic Mayo score, Robarts Histology Index | N/A                                                                                                             | Endoscopic remission group: BWT sigmoid mean reduction, 2.59 ± 1.44 mm, descending colon, 1.82 ± 1.01 mm, p = <0.05. Endoscopic remission showed a cut-off value for BWT in sigmoid ≤2.87 mm [AUROC: 0.91 (0.83–0.99), sensitivity 83% and specificity 100%] and for descending, ≤2.80 mm [AUROC: 0.98 (0.94–1.00), sensitivity 91% and specificity 92%] | N/A           | N/A                                                     | BWT and endoscopic Mayo score showed high correlation [rho 0.68 sigmoid colon, rho 0.75 descending colon, p <0.05]. BWT and Robarts Histology Index moderate correlation [rho 0.49, p <0.05] |
| Author          | Total no. patients | Treatment                                      | Time of assessment | Reference standard | IUS response/remission definition | BWT decrease or no. of patients with/without increased BWT | CDS decrease or number of patients with/without increased CDS | IUS remission association with reference standard |
|-----------------|--------------------|-----------------------------------------------|-------------------|-------------------|-----------------------------------|----------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------|
| Helwig 2021     | 171                | AZA/MTX ± Anti-TNF, Anti-integrin, systemic CS | Baseline, 12 ± 4 weeks | SCCAI             | Response: BWT reduction >25% or a normalisation of BWT. Remission: three different definitions. 1] Normalisation of BWT [ileum ≤2 mm, sigmoid ≤4 mm, rest of colon ≤3 mm] and normalised CDS. 2] Normalised BWT and CDS, restored BWS and no I-fat [minus one factor that could not be assessed]. 3] All factors normalised | 12 weeks: no. of patients with response: 100/131 [76%] | N/A                                                                 | N/A                                                                 |
| Jessen 2020     | 21 CD, 20 UC       | IFX                                           | Baseline, Week 6   | HBI, partial Mayo score | N/A                              | Data not stratified by disease. Responders: median 1 CDS point decrease. Non-responders: median 0 CDS points decrease | N/A                                                                 | N/A                                                                 |
| Kucharzik 2020  | 21 CD, 29 UC       | Biologics, JAK2 inhibitor                      | Baseline, Week 12  | HBI, SCCAI         | Abnormal BWT: sigmoid colon >3 mm, rest of colon and ileum >3 mm | Data not stratified by disease. Pathological segments baseline: 121 [54.8%]. Week 12: 53 [24%], p <0.05 | Data not stratified by disease. Baseline: 25 [50%] patients with increased CDS. Week 12: 7 [14%], p <0.05 | N/A                                                                 | N/A                                                                 |
### Table 2. Continued

| Author | Total no. patients | Treatment Time of assessment | Reference standard | IUS response/remission definition | BWT decrease or no. of patients with/without increased BWT | CDS decrease or number of patients with/without increased CDS | IUS remission | IUS response/remission association with reference standard |
|--------|---------------------|-----------------------------|-------------------|---------------------------------|-----------------------------------------------------|-------------------------------------------------|----------------|----------------------------------------------------|
| Maaser 2020<sup>a</sup> | 244 | 12 Baseline | Stool frequency and rectal bleeding | Abnormal BWT: sigmoid colon >4 mm | N/A | N/A | N/A | Rectal bleeding correlation with abnormal BWT; r = 0.417. Stool frequency correlation with abnormal BWT; r = 0.483. The two combined; r = 0.518 |

Anti-TNF, infliximab, adalimumab, or golimumab; AZA/6-MP, azathioprine/mercaptopurine; AZA/MTX, azathioprine/methotrexate; biologics, no data on which biologics; BWT, bowel wall thickness; CDS, colour Doppler signal; CRP, C-reactive protein; CS, corticosteroids; FCP, faecal calprotectin; IFX, infliximab; N/A, not available; SCCAI, Simple Clinical Colitis Activity Index; TOF, tofacitinib; UC, ulcerative colitis; UC-DAI, Ulcerative Colitis Disease Activity Index; VEDO, vedolizumab; IUS, intestinal ultrasound; IV, intravenous; CD, Crohn’s disease; HBI, Harvey-Bradshaw Index; AUROC, area under receiver operating characteristic curve.

<sup>a</sup>Abstract.

<sup>b</sup>Report data on both Crohn’s disease and ulcerative colitis, stratified by disease.

<sup>c</sup>Report data on both Crohn’s disease and ulcerative colitis, not stratified by disease.
10–14 days, possibly even earlier. Such rapid rates of improvement have not been reported for biologics or immunomodulators. Two years after treatment initiation with either anti-tumour necrosis factor (TNF) or azathioprine, Castiglia et al. showed a significant difference in transmural remission rates by 25% (17/66) vs. 4% (3/67), respectively. In addition, a pediatric [n = 28] and an adult study [n = 234], showed no difference in changes of IUS parameters between patients treated with anti-TNF as monotherapy or in combination with azathioprine, 6 and 12 months after treatment initiation, respectively.

In CD patients, a shorter disease duration (11 ± 8 vs. 19 ± 9 months, p = 0.01) is associated with better IUS and endoscopic responses after 2 years of maintenance treatment with biologics or thiopurines. After 3 months of variable treatment, a divergence of treatment effect can be seen; 41% [n = 16] with disease duration <2 years exhibited improvement, compared with 20% [n = 10] with a disease duration >5 years, p < 0.001. After 12 months [n = 188], the only predictor for higher risk of unchanged/worsened disease was a longer disease duration, p = 0.02 (odds ratio [OR] 3.0, [1.2–7.9]).

Strictures and/or fistulae prognosticate inadequate treatment response, with reported data showing inconsistent results. After 12 weeks of anti-TNF treatment, 33% (3/9) with baseline stenosis or fistula responded to treatment. After 2 years, 17% (1/6) with stenosis responded. Other studies found no response after 12 and 14 months, respectively [0/5, 0/3]. The presence of stenosis before biologic treatment was associated with worse IUS response after 12 weeks, p < 0.001. These rates are much lower than uncomplicated luminal inflammation. Taken together, differences in IUS responses are more likely explained by patient phenotype, disease course, and treatment efficacy than by IUS-specific factors.

Most studies report cross-sectional data on disease location and distribution at baseline but do not report stratified measures during follow-up. Thus, our statements are based on limited evidence.

Figure 2. Risk of bias and applicability—studies from the systematic review, stop date February 27, 2020.

Treatment responsiveness is related to the reversibility of the disease process. In a mixed cohort of patients with inflammatory and stricturing CD, treated with anti-TNF as monotherapy or in combination with azathioprine for 12 weeks, all 33 patients with inflammatory disease responded as determined by reducing BWT, compared with only 6/9 with stricturing disease. After 2 years of treatment, only 17% (1/6) with stricturing disease achieved TR, compared with 23% (9/40) with inflammatory luminal disease. Similarly, Ripoll et al. report an IUS response/remission for 56% [29/51] after 1 year, with no improvement documented in the six patients with stricturing disease. Strictures were the only sonographic feature associated with a negative predictive value for response [p = 0.0001]. The same tendency was reported by Moreno et al., with three colonic strictures at baseline turning into four after a median duration of 14 months, whereas a significant luminal improvement in other
### Table 3. RAND/UCLA process results.

| 3.3. Statements for both Crohn’s disease and ulcerative colitis |
|---------------------------------------------------------------|
| **3.3.1. Machine recommendations**                           | InA | Unc | App  | Total |
| 3.3.1.1. Treatment response can be assessed by intestinal ultrasound | 0   | 0   | 17   | 17    |
| 3.3.1.2. Response should be assessed with:                   |     |     |      |       |
| 3.3.1.2.1. the same type of probe [high-frequency vs. abdominal probe] | 0   | 2   | 15   | 17    |
| 3.3.1.2.2. constant machine settings [Doppler scale, preset, etc.] | 1   | 1   | 15   | 17    |
| **3.3.2. Response rate**                                    |     |     |      |       |
| 3.3.2.1. Response rate detected by intestinal ultrasound is comparable with: |     |     |      |       |
| 3.3.2.1.1. rate of improvement in luminal inflammation, assessed by endoscopy | 0   | 3   | 14   | 17    |
| 3.3.2.1.2. rate of magnetic resonance enterography improvement | 0   | 0   | 17   | 17    |
| 3.3.2.2. Response rate in intestinal ultrasound is depending on: |     |     |      |       |
| 3.3.2.2.1. class of drug [mesalazine vs. steroids vs. immunosuppressants vs. biologics] | 1   | 3   | 13   | 17    |
| 3.3.2.2.2. disease duration [new onset vs. long-term established disease] | 0   | 2   | 15   | 17    |
| 3.3.2.2.3. histological composition of pathological segment [active inflammation only vs. fibrotic only vs. combined] | 0   | 1   | 16   | 17    |
| 3.3.2.3. Response time is generally shorter in ulcerative colitis compared with Crohn’s disease | 0   | 1   | 16   | 17    |
| 3.3.2.4. In responders, colonic disease tends to respond faster with respect to bowel wall thickness than small bowel disease | 0   | 2   | 15   | 17    |
| 3.3.2.5. Response rate in general is different for:          |     |     |      |       |
| 3.3.2.5.1. strictures than luminal disease                   | 0   | 2   | 15   | 17    |
| 3.3.2.5.2. phlegmon vs. luminal disease                     | 0   | 3   | 14   | 17    |
| 3.3.2.5.3. abscesses than luminal disease                   | 0   | 2   | 15   | 17    |
| **3.3.3. Length of disease**                                |     |     |      |       |
| 3.3.3.1. Length in both Crohn's disease and ulcerative colitis should be reported using involved colonic segment[s] [sigmoid colon, descending colon, transverse colon, ascending colon, caecum] | 0   | 0   | 18   | 18    |
| 3.3.3.2. For terminal ileum, length should be reported as distance in cm and distance from ileocaecal valve [if possible] or as proximal small bowel | 0   | 0   | 18   | 18    |
| **3.3.4. Measuring bowel wall thickness**                   |     |     |      |       |
| 3.3.4.1. Response depends on baseline thickness and should be reported in: |     |     |      |       |
| 3.3.4.2. absolute [mm] and relative [%] change from baseline | 2   | 1   | 14   | 17    |
| 3.3.4.3. continuous measurements and is preferred over categories | 0   | 1   | 15   | 16    |
| 3.3.4.4. continuous measurements and should be measured with one decimal for increased precision | 0   | 1   | 16   | 17    |
| 3.3.4.5. continuous measurements, as a mean of two measures in cross-section and two measures in longitudinal orientation | 1   | 1   | 15   | 17    |
| **3.3.5. Defining the worst segment**                      |     |     |      |       |
| 3.3.5.1. The worst segment in both Crohn's disease and ulcerative colitis is defined by the most pathological bowel wall thickness; however, if two segments have the same bowel wall thickness, the order of secondary parameters for defining the worst segment should be the grading of colour Doppler signals, bowel wall stratification, and then inflammatory mesenteric fat, respectively | 0   | 1   | 17   | 18    |
| **3.3.6. Disease activity indices**                        |     |     |      |       |
| 3.3.6.1. If a score is used, the score should summarise measures of all individual segments | 0   | 3   | 14   | 17    |
| 3.3.6.2. Treatment response could be a combined change in one or more activity parameters, specified as a point-reduction from an activity score [present or in the future], bowel wall thickness [continuous], and/or colour Doppler signals [ordinal], and/or bowel wall stratification [ordinal], and/or inflammatory mesenteric fat [ordinal] [IBUS-SAS] | 0   | 3   | 14   | 17    |
3.4. Crohn’s disease

3.4.1. Response definition and timing of assessment in Crohn’s disease

3.4.1.1. Treatment response is identified by reduction of bowel wall thickness [continuous measurements] (>25% or >2.0 mm or >1.0 mm and one colour Doppler signal reduction).

3.4.1.2. Intestinal ultrasound complications that should be assessed for response:

3.4.1.2.1. - strictures
3.4.1.2.2. - phlegmons
3.4.1.2.3. - abscesses

3.4.1.3. Response should initially be assessed in the small and large bowel after treatment initiation [regardless of treatment] at 14 ± 2 weeks. However, in a subset of patients, response after steroids or biologics may occur already after 4 weeks. Early intestinal ultrasound assessment may in certain situations be beneficial between Weeks 4 and 8.

3.4.1.4. Ideal assessment of intestinal ultrasound response within first year of treatment initiation/escalation/change is at baseline, Week 14 ± 2, and between Weeks 26 and 52 + IUS depending on elevated faecal calprotectin or symptoms or clinical suspicion of flare.

3.4.2. Transmural remission, definition and timing of assessment in Crohn’s disease

3.4.2.1. Transmural remission of terminal ileum, small and large bowel is defined by bowel wall thickness ≤3 mm and normal/0 colour Doppler signal.

3.4.2.2. In some patients, sigmoid colon may contain an enlarged muscularis propria [outer hypoechoic layer—typical in diverticular disease], allowing for bowel wall thickness up to 4 mm without resembling active inflammation.

3.4.2.3. Transmural remission should be assessed after treatment initiation [regardless of treatment] between 26 and 52 weeks.

3.4.2.4. Transmural remission may occur already at Week 12 but with increasing likelihood up to 1 [maybe 2] years.

3.5 Ulcerative colitis

3.5.1. Response definition and timing of assessment in ulcerative colitis

3.5.1.1. Treatment response in ulcerative colitis is identified by reduction of bowel wall thickness [continuous measurements] (>25% or >2.0 mm or >1.0 mm and one colour Doppler signal reduction).

3.5.1.2. Ideal assessment of intestinal ultrasound response within first year of treatment initiation/escalation/change is at baseline, Week 14 ± 2, and between Weeks 26 and 52 + IUS depending on elevated faecal calprotectin or symptoms or clinical suspicion of flare.

3.5.1.3. After treatment initiation, response should be measured in all segments that were affected at baseline.

3.5.2. Transmural remission, definition, and timing of assessment in ulcerative colitis

3.5.2.1. Transmural remission in ulcerative colitis of the large bowel is defined by bowel wall thickness ≤3 mm and normal/0 colour Doppler signal.

3.5.2.2. In some patients, sigmoid colon may contain an enlarged muscularis propria [outer hypoechoic layer—typical in diverticular disease], allowing for bowel wall thickness up to 4 mm without resembling active inflammation.

3.5.2.3. Transmural remission in ulcerative colitis should be assessed after treatment initiation [regardless of treatment] at Week 14 ± 2.

3.5.2.4. Transmural remission in ulcerative colitis may occur already at Week 4 but with increasing likelihood up to Week 12 [potentially 1 year].

3.6. Adults vs. paediatric population

3.6.1. The remission/response statements for Crohn’s disease, may be used in both adult and paediatric populations.

3.6.2. The remission/response statements for ulcerative colitis, may be used in both adult and paediatric populations.

Under inappropriate [InA], uncertain [Unc], and appropriate [App], the number of panellists voting as either 1–3, 4–6, or 7–9 is presented.

IBUS-SAS, International Bowel Ultrasound Segmental Activity Score; IUS, intestinal ultrasound.
segments/patients was observed.\textsuperscript{21} In a paediatric study by Civitelli \textit{et al.}, 4/32 had strictureing disease at baseline with no significant improvement after 9–12 months.\textsuperscript{19} In the large TRUST CD trial \(n = 134\), the presence of strictures at baseline was 25\%, followed by 12\% \(p = 0.03\), 10\% \(p = 0.001\), and 9\% \(p \leq 0.001\), at 3, 6, and 12 months respectively. The presence was 5\% for abscesses, followed by 2\%, 1.5\%, and 0.7\%, respectively, non-significant \[NS\]. Both BWT and CDS had higher improvement rates compared with these complications.\textsuperscript{20} No study report data on phlegmons. In the RAND/UCLA process, only one study specifically reported on fistula healing response with a transabdominal approach.\textsuperscript{31} Consequently, statements regarding fistulae were not included in the RAND/UCLA process. Moreno \textit{et al.} \(n = 46\), entero-mesenteric in 70\% recently published a retrospective study, showing that a complete closure of fistulae was achieved in 24/46 \[52\%\] after immunosuppressive treatment, suggesting that IUS could be efficient in monitoring fistulae.\textsuperscript{39} However, high-quality studies focusing on strictures, fistulae, phlegmons, and abscesses are warranted.

### 3.3.3. Length of disease

#### 3.3.3.1. Length in both Crohn’s disease and ulcerative colitis should be reported using involved colonic segment[s] [sigmoid colon, descending colon, transverse colon, ascending colon, cecum]. \[InA. 0, Unc. 0, App. 18\]

#### 3.3.3.2. For the terminal ileum, the length should be reported as distance in cm and distance from the ileocaecal valve [if possible] or as proximal small bowel. \[InA. 0, Unc. 0, App. 18\]

Length of disease is rarely reported in prospective observational trials and almost never included in their IUS response/remission definition. If reported, studies use the extension of disease in centimetres and/or affected bowel segment[s].\textsuperscript{30} Castiglione \textit{et al.} \(n = 40\) CD patients\textsuperscript{8} showed that small bowel length decreased from 35 ± 18 cm at baseline to 20 ± 11 cm after 2 years of treatment with anti-TNF, \(p \leq 0.01\). Corresponding data for MRE were 45 ± 15 cm to 18 ± 12 cm, \(p < 0.001\).\textsuperscript{9} Calabrese \textit{et al.} \(n = 188\) CD patients\textsuperscript{20} showed a decrease of median length [range] of ileal disease from 15 [4–60] cm at baseline, to 10 [0–60] cm after 3 months, 10 [0–60] cm after 6 months, and 10 [0–50] cm after 12 months of treatment with biologics, \(p < 0.05\). Corresponding values for colonic disease were 40 [20–100] cm, 30 [0–100] cm, 20 [0–100] cm, and 10 [0–100] cm, respectively, \(p < 0.05\).\textsuperscript{14} Three pediatric CD studies used similar ways of reporting extension. After treatment with anti-TNF ± immunomodulators, IUS length decreased from 13 ± 5 cm to 8 ± 6 cm after 9–12 months \(n = 32\)\textsuperscript{19} and from 12 ± 5 cm to 9 ± 5 cm [2 weeks], 8 ± 7 cm [4 weeks], 4 ± 4 cm [13 weeks], and 5 ± 6 cm [26 weeks], \(p < 0.0001\) \[n = 28\].\textsuperscript{24} Only in patients with endoscopic response did the extension decrease significantly.\textsuperscript{19} Similar data were reproduced in an abstract \(n = 13\) children, CD\textsuperscript{21} exhibiting a decrease from 11.3 ± 1.4 cm to 6.8 ± 3.8 cm, 14 weeks after treatment initiation.\textsuperscript{81} Another way of reporting the extent of disease is the number of affected segments before and after treatment. In CD patients, 59 segments containing ulcers were evaluated with IUS and endoscopy after a mean treatment period of 14 months with anti-TNF and or immunomodulators. Endoscopy showed remission in 42 segments and IUS showed remission in 37, \(x = 0.76\), \(p = 0.001\). Endoscopy identified 77 affected segments at baseline, and IUS identified 75. During follow-up, the numbers were reduced to 43 and 29, respectively, \(p < 0.001\).\textsuperscript{29} In UC, using X-ray double-contrast barium enema as the reference standard, IUS correctly defined the extension of UC in 74\% of patients, 9/11 with left-sided, 4/7 with subtotal, and 7/9 with pancolitis.\textsuperscript{82} Further, the two largest studies on UC and CD report their data based on segmental involvement, which gives a good overview of the treatment response and/or remission for different segments and thereby the burden of disease over time.\textsuperscript{20,83}

### 3.3.4. Measuring bowel wall thickness

#### 3.3.4.1. Response depends on baseline thickness and should be reported in:

##### 3.3.4.1.1. absolute [mm] and relative [%] change from baseline; \[InA. 2, Unc. 1, App. 14\]

##### 3.3.4.1.2. continuous measurements, preferred over categories; \[InA. 0, Unc. 1, App. 15\]

##### 3.3.4.1.3. continuous measurements within 1 decimal for increased precision; \[InA. 0, Unc. 1, App. 16\]

##### 3.3.4.1.4. continuous measurements, as a mean of two measures in cross-section and two measures in longitudinal orientation. \[InA. 1, Unc. 1, App. 15\]

The exact method for measuring BWT, number of measures, and values are rarely described in observational studies. A standard mode of measurement has recently been suggested by European Federation of Societies for Ultrasound in Medicine and Biology [EFSUMB] and IUS experts.\textsuperscript{62} The latter suggest using continuous numbers with one decimal and a mean of two measures in cross-section and two in longitudinal to avoid any limitation of measuring in one scan plane. This allows for high reliability with an intraclass correlation coefficient [ICC] of 0.96 by 12 readers.\textsuperscript{84} Further, a reduction as low as >0.5mm has been reported for 11/17 with a partial clinical response or remission (based on Crohn’s Disease Activity Index [CDAI] without BWT decline in non-responders, \(p = 0.001\)).\textsuperscript{85} Uncertainty between 0.5 and 1.0 mm may be allowed, and accuracy of mean measurements down to 0.1 mm can be important when assessing minor changes over time. When using BWT to assess treatment response/remission over time, both an absolute and a relative change from baseline should be reported. If only one of the latter is used, different conclusions might be drawn. Categorisation of BWT has been used in several scores and may be combined with other IUS variables.\textsuperscript{63,64} Categorising BWT as a standalone measure is not recommended. For example, if BWT severity class is defined as 3–5 mm, a reduction of 1 mm might result in different activity category, depending on a baseline value of 4.5 mm or 5.5 mm.

### 3.3.5. Defining the worst segment

#### 3.3.5.1. The worst segment in both Crohn’s disease and ulcerative colitis is defined by the most pathological bowel wall thickness; however, if two segments have the same bowel wall thickness, the order of secondary parameters for defining the worst segment should be the grading of colour Doppler signals, bowel wall stratification, and then inflammatory mesenteric fat, respectively. \[InA. 0, Unc. 1, App. 17\]
BWT is the most widely used, reported, and reliable IUS parameter [ICC = 0.96] in clinical observational trials, closely followed by CDS [κ = 0.6]. Increased BWT alone or combined with increased CDS suggests more severe disease. Although less reliable, loss of bowel wall stratification [BWS] is associated with ulcers, and inflammatory fat [I-fat] has been shown to be present in endoscopically active disease only. Combined with our clinical experience, we suggest that BWS and I-fat can be used as contributory parameters when assessing the worst segment. However, since the interrater reliability of IUS parameters assessed by 12 IUS experts in CD patients was low to moderate for BWS and I-fat, κ = 0.39 and κ = 0.51, respectively, assessment of these parameters should be carefully considered in combination with more reliable parameters. In UC, the interrater reliability between two experts was 0.92 for BWT and 0.60–0.79 for CDS [depending on disease location]. No data are reported for I-fat or BWS. In addition, De Voogd et al. showed 30 cine-loop cases to six IUS experts, resulting in an ICC of 0.96 for BWT, κ = 0.63 for CDS, κ = 0.36 for I-fat, and κ = 0.24 for BWS, further confirming the high interrater variability between I-fat and BWS.

3.3.6. Disease activity indices

3.3.6.1. If a score is used, the score should summarise measures of all individual segments. [InA. 0, Unc. 3, App. 14]

3.3.6.2. Treatment response could be a combined change in one or more activity parameters, specified as a point reduction from an activity score [present or in the future], bowel wall thickness [continuous] and/or colour Doppler signals [ordinal], and/or bowel wall stratification [ordinal] and/or inflammatory mesenteric fat [ordinal]. [InA. 0, Unc. 3, App. 14]

Empirically, IUS response and remission rates for both CD and UC are prone to considerable variation between patients and can occur segmentally. We therefore recommend measurements from all segments to be included in a future responsive score for the assessment of treatment response. Further, a future validated score should focus on responsiveness and define levels on responsiveness and define levels on response and remission, like the validated Maria and simple Maria scores for MRE. Most of the current scores that use BWT, CDS, BWS, and I-fat generally correlate well with their respective reference standard. However, two recent systematic reviews both conclude that no current published score is validated. After the RAND/UCLA process, several new scores have been published, using different combinations of BWT, CDS, BWS, I-fat, clinical symptoms, contrast IUS, and elastography. Interestingly, Saevik et al. used only BWT and CDS in their score, excluding BWS and I-fat due to poor interobserver agreement. In our opinion, no score using continuous measures of BWT is sufficiently validated for responsiveness, and future extensive validation studies are warranted before any specific score can be recommended.

3.4. Crohn’s disease

3.4.1. Response definition and timing of assessment in Crohn’s disease

3.4.1.1. Treatment response is identified by reduction of bowel wall thickness [continuous measurements] [>25%] or [>2.0 mm] or [>1.0 mm and one colour Doppler signal reduction]. [InA. 0, Unc. 3, App. 15]

3.4.1.2. Intestinal ultrasound complications that should be assessed for response:

3.4.1.2.1. strictures; [InA. 0, Unc. 2, App. 15]

3.4.1.2.2. phlegmons; [InA. 0, Unc. 3, App. 14]

3.4.1.2.3. Abscesses. [InA. 1, Unc. 3, App. 13]

3.4.1.3. Response should initially be assessed in the small and large bowel after treatment initiation [regardless of treatment] at 14 ± 2 weeks. However, in a subset of patients, response after steroids or biologics may occur already after 4 weeks. Early intestinal ultrasound assessment may, in certain situations, be beneficial between weeks 4 and 8. [InA. 0, Unc. 0, App. 17]

3.4.1.4. Ideal assessment of intestinal ultrasound response within the first year of treatment initiation/escalation/change is at baseline, week 14 ± 2, AND between week 26–52 + IUS depending on elevated f-Calprotectin OR symptoms OR clinical suspicion of flare. [InA. 1, Unc. 1, App. 15]

Different prospective definitions of IUS treatment response have been proposed in the literature, primarily using BWT alone or in combination with CDS [Table 2, Supplementary Table 2 and 3]. Few of these definitions are correlated with clinical outcomes. Although not part of the response definition, both strictures, phlegmons, and abscesses should be reported when assessing response, especially if interested in disease prognosis. These complications are identified utilizing the recommendations from the EFSUMB group.

3.4.1.5. Bowel wall thickness

After 2 weeks of variable treatment, absolute and relative reductions in BWT of 0.6–0.9 mm [11–16%] have been reported. After 4 weeks the BWT was reduced to 0.3–1.3 mm, [5–23%]. After 12 weeks to 0.01–3.0 mm [0.2–43%], after 6 months to 1.0–1.9 mm [17–34%], after 1 year to 1.4–2.35 mm [22–34%], and after 2 years to 2.0–2.2 mm [33–36%]. Only one study investigated azathioprine monotherapy and found a non-significant reduction of 0.4 mm [6%] after 2 years. Unfortunately, in most of these studies, responders and non-responders were reported together. Consequently, a group treatment effect is seen rather than an isolated effect reflecting endoscopic response. Data heterogeneity may indeed reflect diversity in reporting and patient populations among studies. Both absolute and relative reductions were increased when only focusing on treatment responders [defined by clinical scores].
After 4 weeks of any treatment, BWT decreased by 2.2 mm as opposed to 0.9 mm in the non-response group, \( p < 0.05 \). 23 After 6–18 weeks, BWT decreased by 3.0 mm [43%] as opposed to 1.0 mm [14%], \( p = 0.01 \). \( \text{[N/A]} \). 29 After 12 weeks, BWT decreased by 1.5 mm [24%] and 1.2 mm [19%] as opposed to 0.1 mm, \( p = 0.01 \), in the non-response group. \( \text{[N/A]} \). 27 A median reduction of 1.7 mm in 13 patients after 3 months of treatment, compared with a reduction in Simple Endoscopic Score in CD [SES-CD], showed \( \rho = 0.65, p = 0.015 \). 27

### 3.4.1.6. Colour Doppler signal

Most studies apply the original or a modified version of the ordinal Limberg score [0–4] \( \text{[N/A]} \) and report the number of patients with stable or declined CDS at each time point. CDS response is usually accompanied by a reduction of BWT between 0.5 to 2.0 mm or by 25% in prospective response definitions [see Tables 1 and 2; and Supplementary Tables 2 and 3]. It is therefore difficult to assess the impact of a CDS reduction alone on clinical outcomes. Only two studies investigated this specifically. Ripolles et al. showed that 17/28 treated with 5-ASA, or with corticosteroids as monotherapy or combined with azathioprine, experienced relapse or needed surgery during follow-up. At Week 4, 76% had an increased CDS compared with 18% in the non-relapse group, \( p < 0.01 \). 22 A mean reduction of 2.7 CDS points was reported in those achieving long-term remission [1-year follow-up] compared with 1.2 points in non-responders, \( p = 0.014 \). 80 Therefore, a sole reduction of one CDS point without subsequent reduction in BWT is likely insufficient to predict baseline good long-term outcomes. Increased CDS is not always detected at baseline, even with an increase in BWT. In general, one can expect that between 39% and 80% have an elevated baseline CDS [Limberg ≥2]. 16,17,19,41,82 Ripolles et al. found an early improvement in CDS after 3–8 days of treatment in 23%, followed by 32% with normalised CDS after 4 weeks. 22

In conclusion, based on this evidence, a reduction in BWT of >25% or [≥2.0 mm or [≥1.0 mm with one CDS grade reduction] seems to be accurate when defining treatment response.

### 3.4.1.7. Timing of response assessment

Kucharzik et al. \( n = 182 \) observed a 10% or 25% reduction of BWT in 95% and 80% of patients after 3 months, respectively. Like BWT, a reduction of CDS mainly occurs within the first 3 months. However, continuous improvement is seen for ileal disease as previously outlined. 20 Ripolles et al. showed that 22/26 patients with a prospectively defined sonographic improvement [BWT normalisation or decrease of ≥2 mm with a decrease of one CDS grade] after 12 weeks continued with further improvement at 52 weeks; data were not stratified for type of segment. Further, the response at 12 weeks seems to predict response at 52 weeks with a sensitivity of 76% and a specificity of 82%, odds ratio of 14. 14 Dillman et al. \( n = 28 \), paediatrics] performed a regression analysis and found that a mean daily reduction in BWT after infliximab [IFX] treatment was 0.004 mm after adjustment for covariates. It took 2 weeks for BWT and CDS to reach a significant reduction, which was maintained at follow-up visits after 1, 3, and 6 months. 14

### 3.4.2. Transmural remission, definition, and timing of assessment in Crohn’s disease

#### 3.4.2.1. Transmural remission of the small and large bowel

is defined by bowel wall thickness ≤3 mm with normal/0 colour Doppler signal. [InA. 0, Unc. 1, App. 17]

#### 3.4.2.2. In some patients, sigmoid colon may contain an enlarged muscularis propria [outer hypoechogenic layer typical in diverticular disease], allowing for bowel wall thickness up to 4 mm without resembling active inflammation. [InA. 3, Unc. 1, App. 13]

#### 3.4.2.3. Transmural remission should be assessed after treatment initiation [regardless of treatment] between 26 and 52 weeks. [InA. 0, Unc. 3, App. 14]

#### 3.4.2.4. Transmural remission may occur already at Week 12 but with increasing likelihood up to 1 year [maybe 2 years]. [InA. 0, Unc. 0, App. 17]

No expert consensus on the definition of TR has previously existed. 8 We recognise that a BWT ≤4 mm of the sigmoid can be normal for some patients, especially if diverticula are present. However, based on the studies from Castiglione et al. 18,19,53 and Moreno et al. 25 combined with our own expert opinion, a majority of the panel recommend defining TR as BWT ≤3 mm with normal CDS for both small and large bowel. This definition is consistent with the definition previously suggested in the article by Geyl et al. 84 and with the recommendation from Goodall et al. for clinical trials. 81 Based on cross-sectional studies, a BWT cut-off value of 3 mm gives a sensitivity of 89% and a specificity of 96% in detecting inflammation. 7 Further, a recent systematic review and meta-analysis, based on both CD and UC, concluded that a colorectal segment ≤3 mm is highly likely to be present in segments achieving endoscopic remission [ER] [negative predictive value 92.7%]. 86 With this definition, one can expect that between 20% and 30% will achieve TR after 12 weeks, 26,27 with 30–50% achieving TR after 1 year on biologics. 16,27

#### 3.4.2.5. BWT and its association with transmural remission

The most used definition of IUSTR in prospective observational trials is BWT ≤3 mm alone or in combination with other IUS parameters [Table 1; Supplementary Tables 2 and 3]. 1,4 BWT ≤3 mm alone has a substantial association with endoscopic remission [ER] [defined as the absence of ulcerations, SES-CD <2, \( \kappa = 0.63, p = 0.01 \)14,19 and an almost perfect agreement with TR assessed by MRE [defined as BWT ≤3 mm without signs of hypervascularisation, \( \kappa = 0.9, p ≤0.01 \). As expected, 2 BWT ≤3 mm alone has a fair association with clinical remission [CDAI <150], \( \kappa = 0.27, p ≤0.01 \), and a substantial association with C-reactive protein [CRP], \( \kappa = 0.79, p = 0.02 \). 14,19 These data are derived from two studies which, combined, focused on TR rates in 173 patients 2 years after treatment with anti-TNF. The same research group compared 1-year clinical outcomes with three different groups: TR combined with ER \( n = 68 \), ER alone \( n = 60 \), and without objective evidence of remission \( n = 90 \). TR
### Table 4. Crohn’s disease—proportion of patients achieving transmural remission at each assessment.

| Transmural remission definition | Treatment                                                                 | Week 4 | Week 8 | Week 8 - 12 | Weeks 12–16 | 6 months | 9–12 months | 14–18 months | 2 years | 3 years |
|--------------------------------|----------------------------------------------------------------------------|--------|--------|-------------|-------------|----------|-------------|-------------|---------|---------|
| BWT ≤3 mm                      | Anti-TNFAZA/6-MP                                                           |        |        |             |             |          |             |             |         |         |
|                                |                                                                            | 27%    | 30%    |             |             |          |             |             |         |         |
|                                | Anti-TNFAZA/6-MP + 5-ASA                                                  |        |        |             |             |          |             |             |         |         |
|                                |                                                                            | 30%    | 30%    |             |             |          |             |             |         |         |
| BWT ≤3 mm and CDS 0 to 1       | Anti-TNF                                                                  | 21%    | 29%    |             |             |          |             |             |         |         |
| BWT ≤3 mm small bowel, ≤4 mm colon<sup>a</sup> | Anti-TNF                                                                |        |        |             |             |          |             |             |         |         |
|                                | Biologics                                                                 |        |        |             |             |          |             |             |         |         |
|                                |                                                                            | 16%    | 25%    |             |             |          |             |             |         |         |
| BWT ≤3 mm small bowel, ≤4 mm large bowel, CDS 0<sup>b</sup> | Anti-TNF                                                                |        |        |             |             |          |             |             |         |         |
|                                |                                                                            |        |        |             |             |          |             |             |         |         |
| BWT ≤2 mm small bowel, ≤3 mm colon, CDS score ≤1<sup>c</sup> | Anti-TNF                                                                |        |        |             |             |          |             |             |         |         |
|                                |                                                                            | 2%     | 6%     |             |             |          |             |             |         |         |
| BWT ≤3 mm, normalisation of CDS<sup>d</sup> | Anti-TNF                                                                |        |        |             |             |          |             |             |         |         |
|                                |                                                                            |        |        |             |             |          |             |             |         |         |
| BWT ≤3 mm, normalisation of CDS<sup>e</sup> | Anti-TNF                                                                |        |        |             |             |          |             |             |         |         |
|                                | ±AZA/6-MP, 5-ASA                                                           |        |        |             |             |          |             |             |         |         |
| BWT ileum ≤2 mm, sigmoid ≤4 mm, rest of colon ≤3 mm, normalization of CDS | Anti-TNF + Anti-integrin, systemic CS                                    | 32%    |        |             |             |          |             |             |         |         |
|                                | AZA/MTX                                                                  |        |        |             |             |          |             |             |         |         |
| BWT ileum ≤2 mm, sigmoid ≤4 mm, rest of colon ≤3 mm, normalization of CDS, restored BWS and no I-fat [minus one factor that could not be assessed] | Anti-TNF + Anti-integrin, systemic CS                                    | 37%    |        |             |             |          |             |             |         |         |
|                                | AZA/MTX                                                                  |        |        |             |             |          |             |             |         |         |
| BWT ileum ≤2 mm, sigmoid ≤4 mm, rest of colon ≤3 mm, normalization of CDS [Limberg 1/2], restored BWS and no I-fat | Anti-TNF + Anti-integrin, systemic CS                                    | 24%    |        |             |             |          |             |             |         |         |

<sup>a</sup>Normal bowel wall stratification and absence of inflammatory fat.

<sup>b</sup>No length of disease, normal bowel wall stratification, no inflammatory fat, no active inflammation or fistulising disease.

<sup>c</sup>No length of disease, absence of fistulae, phlegmons, or abscesses.

<sup>d</sup>No lymph node enlargement or presence of strictures or pre-stenotic dilation.

5-ASA, mesalazine; anti-TNF, infliximab; adalimumab; AZA/6-MP, azathioprine/mercaptopurine; biologics, infliximab, adalimumab, ustekinumab, vedolizumab; BWS, bowel wall stratification; BWT, bowel wall thickness; CDS, colour Doppler signals; I-fat, inflammatory fat; UST, ustekinumab; CS, corticosteroid.
[BWT ≤3 mm] was associated with higher rates of steroid-free clinical remission (96%, hazard ratio [HR] 0.87, p < 0.01), lower rates of hospitalization [9%, HR 0.88, p < 0.01], need for surgery [0%, HR 0.94, p < 0.01] compared with ER. Even for patients discontinuing anti-TNF treatment, TR predicted better clinical outcomes compared with ER, p < 0.01.14 Defining TR as BWT ≤3 mm for small bowel, ≤4 mm for large bowel, no length of disease, and absence of fistula, TR often occurs within the first 3 months of treatment, followed by 24 and 36 months, the rates were 20% [9/46] and 24% [8/33],17 This is further supported by the STARDUST study, where thiopurines, 26% [17/66] vs. 5% [3/67],18 no significant differences were shown a significant difference in TR rates between anti-TNF and the maintained presence of extra-mural inflammation [e.g. I-fat] can be a sign of chronic disease. BWS and I-fat might be included in future definitions of response/remission. However, we suggest that these parameters are mainly contributory to disease activity assessment and could be integrated with more important parameters. We believe that the definition of TR varies among studies. Depending on disease severity, the treatment used, disease location, and the IUS parameters included, remission rates vary Table 4. While Castiglia et al. showed a significant difference in TR rates between anti-TNF and thiopurines, 26% [17/66] vs. 5% [3/67],19 no significant differences exist between biologic treatments.18,19,34 However, a newly published study by Calabrese et al. found that ustekinumab had a lower chance of achieving TR. Authors acknowledge that ustekinumab is offered for refractory diseases, which may influence their findings.14 Further, these studies are, therefore, primarily based on our clinical experience and expert opinion. After 2–3 weeks of steroid/cytopheresis treatment, 42% [11/26] showed a BWT reduction by ≥2.5 mm. One-year clinical remission was found in 9% [1/11] in the non-response group, compared with 47% [9/15] in the non-response group, p < 0.05.25 After 2 months of treatment with steroids, Maconi et al. [n = 30] showed a significant decrease in BWT by 2.3 mm [31%] in the response group alone.41 Already after 10 days of steroid treatment, a significant decrease in BWT meant no risk of surgery at 3 months, n = 32 [25 moderate/severe based on the Truelove–Witts score].49 In clinical experience, patients receiving steroids tend to respond faster than patients receiving biologics. It is still unclear if transabdominal IUS response

3.4.3. Other important intestinal ultrasound parameters that are not included in the definition of response and transmural remission

BWT and CDS appear to be the most important parameters when assessing IUS response and remission, based on their relationship with clinical outcomes. Although deemed important by experts, I-fat and BWS are not included in our current definition of response or remission/TR. Current data on BWS suggest that up to 53% with active CD will have a loss of BWS, with gradual restoration of BWS after 3 months of treatment to 29%, followed by 22% at both 6 and 12 months, p < 0.001.20 Other studies have not reported a significant restoration of BWS over time.19 In active CD, I-fat might be present in up to half of the patients before treatment initiation, with a more apparent decline after 3 months of treatment to 22% followed by 17–18% at 6 and 12 months, respectively, p < 0.001.20 Currently, no study has correlated BWS or I-fat with clinical outcomes. However, mesenteric adipose tissue proliferation correlates with increased BWT [OR 7.6] and internal fistulae [OR 13.5].29 We believe that the definition of TR varies among studies. Depending on disease severity, the treatment used, disease location, and the IUS parameters included, remission rates vary Table 4. While Castiglia et al. showed a significant difference in TR rates between anti-TNF and thiopurines, 26% [17/66] vs. 5% [3/67],19 no significant differences exist between biologic treatments.18,19,34 However, a newly published study by Calabrese et al. found that ustekinumab had a lower chance of achieving TR. Authors acknowledge that ustekinumab is offered for refractory diseases, which may influence their findings.14 Further, these studies are, therefore, primarily based on our clinical experience and expert opinion. After 2–3 weeks of steroid/cytopheresis treatment, 42% [11/26] showed a BWT reduction by ≥2.5 mm. One-year clinical remission was found in 9% [1/11] in the non-response group, compared with 47% [9/15] in the non-response group, p < 0.05.25 After 2 months of treatment with steroids, Maconi et al. [n = 30] showed a significant decrease in BWT by 2.3 mm [31%] in the response group alone.41 Already after 10 days of steroid treatment, a significant decrease in BWT meant no risk of surgery at 3 months, n = 32 [25 moderate/severe based on the Truelove–Witts score].49 In clinical experience, patients receiving steroids tend to respond faster than patients receiving biologics. It is still unclear if transabdominal IUS response

3.5. Ulcerative colitis

3.5.1. Response definition and timing of assessment in ulcerative colitis

3.5.1.1. Treatment response in ulcerative colitis is identified by reduction of bowel wall thickness [continues measurements] ≥25% or ≥2.0 mm or >1.0 mm and one colour Doppler signal reduction. [InA. 0, Unc. 3, App. 15]

3.5.1.2. Ideal assessment of intestinal ultrasound response within the first year of treatment initiation/escalation/change is at baseline, Week 14 ± 2, and between Weeks 26–52 + intestinal ultrasound depending on elevated faecal calprotectin or symptoms or clinical suspicion of flare. [InA. 0, Unc. 2, App. 14]

3.5.1.3. After treatment initiation, response should be measured in all segments that were affected at baseline. [InA. 0, Unc. 0, App. 14]
can be measured earlier than at 2 weeks. This doubt reflects the lack of consensus for statements on early response in acute severe ulcerative colitis [Supplementary Material 2, second round voting results, 44.2]. However, a recent pilot study \(n = 10\) on steroid treatment in severe acute UC showed that IUS performed within the first 48 h of hospitalization potentially predicts treatment outcome.91

Focusing on anti-TNF in UC, a BWT reduction in 34% \([15/44]\) is shown after 6 weeks in the sigmoid and descending colon. Further, patients with an increased CDS at Weeks 6 and 12 had a significantly higher simple clinical colitis activity index [SCCAI], compared with no CDS signal, \(p \leq 0.001.44\) After 14 weeks of vedolizumab treatment, 57% \([4/7]\) achieved BWT reduction of 1.0 mm, \(p = \text{N/A},\) in the response group alone. CDS significantly decreased from 1.3 to 0.5 in responders and increased from 1.3 to 2.7 in non-responders, \(p \leq 0.05.28\)

After the RAND/UCLA process, De Voogd et al. \([n = 29]\) published an abstract showing a mean BWT reduction of 2.6 ± 1.4 mm for the sigmoid and 1.8 ± 1.0 mm for the descending colon in patients achieving ER on tofacitinib treatment.40 Further, Helwig et al. showed that 76% \([100/171]\) achieved a greater than 25% BWT reduction after 12 weeks of mixed treatment.37

This limited available evidence suggests using the exact definition of treatment response in UC as for CD. However, more studies are needed, and no pediatric studies were identified.

### 3.5.2. Transmural remission, definition, and timing of assessment in ulcerative colitis.

- **3.5.2.1. Transmural remission in ulcerative colitis of the large bowel is defined by bowel wall thickness ≤3 mm with normal/0 colour Doppler signal.** [InA. 0, Unc. 1, App. 17]

- **3.5.2.2. In some patients, sigmoid colon may contain an enlarged muscularis propria [outer hypoechoic layer—typical in diverticular disease], allowing for bowel wall thickness up to 4 mm without resembling active inflammation.** [InA. 3, Unc. 1, App. 13]

- **3.5.2.3. Transmural remission in ulcerative colitis should be assessed after treatment initiation [regardless of treatment] at Week 14 ± 2.** [InA. 0, Unc. 2, App. 16]

- **3.5.2.4. Transmural remission in ulcerative colitis may occur already at Week 4 but with increasing likelihood up to Week 12 [potentially 1 year].** [InA. 1, Unc. 3, App. 14]

Before the RAND/UCLA process, no study had explicitly defined TR for UC. Given the common understanding that UC is not considered a transmural disease, one could argue that no definition of TR is needed [Table 2]. However, numerous examples of extra-mural inflammation, like I-fat and enlarged lymph nodes, in moderate and severe UC challenges the classification of UC as a disease limited to the mucosa only.40 As a consequence, we believe that a definition of TR is valid and vital for future studies examining the role of IUS remission and its’ relationship with clinical outcomes during follow-up for UC patients. After 2 weeks of variable treatment \(n = 224\), the proportion of patients with increased BWT in the sigmoid colon was reduced from 89% to 39%, \(p < 0.001.\) A further improvement at Weeks 6 and 12 were shown, at 35% and 32%, respectively, \(p \leq 0.001.\) A thickened bowel wall was present in 83% at baseline in the descending colon, followed by a significant decrease to 43% at both Weeks 2 and 6. Endoscopy was not routinely performed during follow-up. However, the IUS findings had a moderate association with SCCAI and faecal calprotectin [FC]. In sigmoid colon, baseline CDS was increased by 35%, followed by 23%, 16%, and 13% at Weeks 2, 6, and 12, \(p < 0.001.\) The proportion of patients with an increased CDS in the descending colon were 15% at baseline, followed by 7%, 5%, and 7%, \(p < 0.001.\) In 5/6 patients with ER and clinical remission, BWT was ≤4 mm after 2 months of various treatments. BWT was significantly higher in the pre-treatment group with moderate/severe clinical and endoscopic activity compared with the mild endoscopic group.41 These findings report a considerable improvement in BWT and CDS within the first 12 weeks of treatment. By combining BWT and CDS in a 0–3 score and comparing it with the 0–3 Baron endoscopic score, Paredes et al. showed substantial reliability, \(\kappa = 0.76,\) at 3 months, and almost perfect \(\kappa = 0.88–0.90\) at 9 months and 15 months, respectively.39 After 8 weeks of treatment with tofacitinib, de Voogd et al. \([n = 29]\) showed that all patients in the ER group had a BWT cut-off value of ≤2.9 mm [area under the receiver operating characteristic curve [AUROC] 0.91 [0.83–0.99], sensitivity 83%, and specificity 100%] in the sigmoid colon and ≤2.8 mm [AUROC 0.98 [0.94–1.00], sensitivity 91%, and specificity 92%] for descending colon.46 Helwig et al. \([n = 171]\) examined three different definitions of TR. Focusing on the definition containing BWT and CDS, 12-week TR rates were 53%. This high rate could be explained by a BWT cut-off value of 4 mm in the sigmoid and a CDS score of 1–2 defined as normal.37 A recent systematic review of cross-sectional studies concluded that the most often used criteria to define disease activity were BWT and CDS. The evidence also suggests that BWT in combination with CDS or BWS gives a more accurate correlation with other markers of disease activity.4

Although based upon limited evidence, most of the experts in our panel believe that the same definition for TR in CD is applicable in UC.

### 3.5.3. Additional relevant IUS parameters

The TRUSTandUC study showed that 40%, 23%, and 57% have a presence of I-fat, loss of BWS, and loss of haustration at baseline, respectively. All parameters significantly improved 12 weeks later. These parameters are contributory in the assessment of UC activity by IUS. However, there are no current data on their relationship with clinical outcomes over time and consequently they are not included in our definition. However, they might be included in a validated future score for response and remission, as previously discussed.

### 3.6. Adults vs. pediatric population

- **3.6.1. The remission/response statements for Crohn’s disease may be used in both adult and pediatric populations.** [InA. 2, Unc. 1, App. 14]

- **3.6.2. The remission/response statements for ulcerative colitis may be used in both adult and pediatric populations.** [InA. 2, Unc. 2, App. 12]

There was only one pediatrician involved in our RAND/UCLA process. However, based on the limited available evidence from pediatric studies presented throughout this article [Supplementary Table 3],46,19,61,48,92,93 we find that our recommendations may be used in both populations. Future studies are needed to validate or refute this assumption.
4. Discussion

Cross-sectional imaging, an objective biomarker, currently gains increasing attention and incorporation into clinical trials as a proposed treatment target. IUS is an accurate, reliable, cost-effective, patient-friendly, non-invasive imaging modality performed by clinicians in a point-of-care setting. However, definitions for imaging response and transmural remission/healing and optimal assessment timing currently lack international consensus. This systematic review demonstrates the diversity in the current literature of IUS response definitions and reporting. Using a robust methodology, the eligible studies included patients with different disease characteristics [severity and location], treatments, times to follow-up, reference standards, aims, and outcomes. This further highlights the need for an international expert consensus on IUS response assessment and reporting. We now provide clear international expert consensus defining optimal timing and cut-offs for transmural response and remission for CD and UC, using IUS. We also establish consensus recommendations on imaging acquisition, expected transmural response time, disease length, measuring and reporting bowel wall thickness, defining worst bowel segment, the composition of disease activity indices, and paediatric applicability.

Our study has several strengths. Not only did we perform a comprehensive systematic review, we also added a novel and robust RAND/UCLA process, with a panel including many of the world’s leading IBD IUS researchers. Using this methodology, panels are not forced into a majority agreement but individual rating statements on an appropriateness scale. Indeed, statements reached agreement on appropriate definitions for IUS response reporting, preceded by high-level and intense discussions. Not all researchers voted on all statements, and one additional expert was added during the second round. This is reflected by the different total vote counts, especially between CD and UC statements. Due to the small amount of data and the experts’ area of expertise limitations, UC statements received fewer votes.

Limitations of this study include the limited amount of high-quality prospective evidence, leaving the panel with an agreement based upon the available literature and expert experience. The applicability of the included research to answer our study questions was high, but so was the risk of bias. A large proportion of the uncertain or unknown biases comes from the included abstracts. Due to the expected low number of full-text studies, the inclusion of abstracts was deemed necessary. Another high risk of bias is the large proportion of data and the experts’ area of expertise limitations, UC statements received fewer votes.

With only six studies using ER and/or MRE as a reference standard, definitions of response were influenced by all included studies. In addition, a couple of pivotal studies were published after the first literature search. Since they were aligned with our voting, we chose to add them to the supporting text, although they were not part of the systematic review itself. We aimed at rating individual statements by the Grading of Recommendations, Assessment, Development, and Evaluations [GRADE] terminology. However, observational studies per se are considered low certainty evidence, potentially further downgraded to very low certainty by the limitations reported by the risk of bias. In the absence of any randomised controlled trials using IUS in IBD patients, all our recommendations are considered weak.

However, we hope these consensus definitions and recommendations will guide future high-quality prospective therapeutic trials using IUS as a secondary or primary endpoint, eventually leading to broad adoption of intestinal ultrasound as the standard of care in objective disease monitoring in IBD striving towards achieving TR.

In conclusion, an agreement was reached on 43 different appropriate statements, including clear definitions on IUS treatment response, transmural remission, optimal timing of follow-up, and general considerations for using transabdominal intestinal ultrasound in inflammatory bowel disease. To ensure a unified approach in routine care and clinical trials, we provide recommendations and definitions for incorporation in future prospective studies.

Funding

Travel grant (received 25 000 DKK) from the Danish Society of Gastroenterology and Hepatology together with Takeda; the Leona M. and Harry B. Helmsley Charitable Trust.

Conflict of Interest

JFKFI has received research grants from Takeda, Janssen, ParaTech, the Danish Research Council, and the Capital Region of Denmark. TH has received support from Johnson and Johnson and Takeda for advisory boards. TMG has received support through provision of an Australian Government research training programme scholarship and grant support from Janssen. JBS has received research grants from Takeda, Janssen, the Danish Research Council, and the Capital Region of Denmark, and is national coordinator of studies from AbbVie, Arena Pharmaceuticals, Eli Lilly, and Boehringer Ingelheim. HA-F has received consultancy and speaker fees from Takeda, AbbVie, Janssen, and Pfizer. MA has received consulting fees from Nikkise, Europe, Mundipharma, Janssen, Abbvie, and Pfizer. JB has received honoraria, research grants, or consulting fees from Abbvie, Janssen, Takeda, Pfizer, Ferring, Bristol Myers Squibb, Gilead, Tillotts, Sandoz, Chiesi, Celltrion, Microbiota, Antara, Research Review, NHMRC, US Department of Defense, Gutty Foundation, Gastroenterological Society of Australia, Viertel Foundation, and Mater Foundation. RVB has received grant/research support/speaker fees [all paid to employer for research support]: AbbVie, Ferring, Janssen, Shire, Takeda, Emerge Health; shareholding: BiomeBank. RG has received grants from Abbvie, Janssen, Pfizer, Takeda, and Ferring and served on the advisory boards of Abbvie, Janssen, and Novartis. MC has received consultancy fees from Abbvie, Arena, RBS, Celgene, Janssen, Pfizer, Prometheus Labs, Takeda, and grant support from Abbvie, Janssen. KBG has received grants from Pfizer and Celltrion, consultancy fees from Abbvie, Arena Pharmaceuticals, Galapagos, Gilead, ImmunoTherapeutics, Janssen Pharmaceuticals, Novartis, Pfizer, Samsung Bioepis, and Takeda, and speaker’s honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer, Samsung Bioepis, Takeda, and Tillotts. TK has received honoraria from Abbvie, Amgen, Celgene, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Gilead, Hospira, Mundipharma, Dr. Falk Pharma GmbH, Janssen, MSD Sharp and Dome GmbH, Pfizer, Takeda Pharma GmbH. CH has received consultancy fees from Abbvie, Arena, BMS, Celgene, Janssen, Pfizer, Prometheus Labs, Takeda, and grant support from Abbvie, Janssen. KBG has received grants from Pfizer and Celltrion, consultancy fees from Abbvie, Arena Pharmaceuticals, Galapagos, Gilead, ImmunoTherapeutics, Janssen Pharmaceuticals, Novartis, Pfizer, Samsung Bioepis, and Takeda. CM has received grants/personal fees from Abbvie, Biogen, Galapagos, Dr. Falk Pharma GmbH, Ferring Arzneimittel GmbH, Gilead, Janssen, MSD Sharp and Dome GmbH, Pfizer, Roche, Takeda Pharma GmbH, Vifor Pharma. GM has received consulting fees from and served on the advisory boards of Alfa Sigma, Arena Pharmaceuticals, Gilead, Janssen, and Roche. KN has received speaker honoraria from Takeda. CP has received grants/personal fees from Janssen and Laboratorios Vitória. SRW has received research grants from Samsung, equipment support from Philips, Samsung, and Siemens. KN has received advisory board fees from Abbvie, Janssen, Pfizer, Ferring, and Takeda, speaker’s fees from Abbvie, Janssen, and Pfizer, and research support from Abbvie and Janssen. RW has received grants/personal fees from Janssen, Takeda, Pfizer, Abbvie, Alimentiv.
Authors Contributions
JKF: conceptualisation, methodology, validation, formal analysis, investigation, data curation, writing—original draft, writing—review and editing, supervision, project administration. TH: validation, investigation, data curation, writing—review and editing. TMG: validation, investigation, data curation, writing—review and editing. JB: data curation, writing—review and editing. KN: conceptualization, methodology, data curation, writing—review and editing. CM: data curation, writing—review and editing. MA: data curation, writing—review and editing. JBS: data curation, writing—original draft, writing—review and editing. JB: data curation, writing—review and editing. RV: data curation, writing—review and editing. RB: data curation, writing—review and editing. DC: data curation, writing—review and editing. KC: data curation, writing—review and editing. TC: data curation, writing—review and editing. CL: data curation, writing—review and editing. CM: data curation, writing—review and editing. GM: data curation, writing—review and editing. KN: data curation, writing—review and editing. CP: data curation, writing—review and editing. SW: data curation, writing—review and editing. KN: conceptualization, methodology, data curation, writing—original draft, writing—review and editing. RV: conceptualisation, methodology, validation, data curation, writing—original draft, writing—review and editing, visualisation, project administration.

Supplementary Data
Supplementary data are available at ECCO-JCC online.

References
1. Maaser C, Sturm A, Vavricka SR, et al. European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD. Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144–64.
2. Bryant RV, Friedman AB, Wright EK, et al. Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut 2018;67:973–85.
3. Rajagopalan A, Sanathanan D, An YK, et al. Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge. JGH Open 2020;4:267–72.
4. Smith RL, Taylor KM, Friedman AB, Gibson RN, Gibson PR. Systematic review: clinical utility of gastrointestinal ultrasound in the diagnosis, assessment, and management of patients with ulcerative colitis. J Crohns Colitis 2020;14:466–79.
5. Dong J, Wang H, Zhao J, et al. Ultrasound as a diagnostic tool in detecting active Crohn’s disease: a meta-analysis of prospective studies. Eur Radiol 2014;24:26–33.
6. Maconi G, Nyulund K, Ripollés T, et al. EFSUMB Recommendations and Clinical Guidelines for Intestinal Ultrasound [GIUS] in Inflammatory Bowel Diseases. Ultraschall Med 2018;39:304–17.
7. Goodsall TM, Nguyen TM, Parker CE, et al. Systematic review: Gastrointestinal ultrasound scoring indices for inflammatory bowel disease. J Crohns Colitis 2021;15:609–14.
8. Wilkins R, Novak KL, Maaser C, Panaccione R, Kucharzik T. Relevance of monitoring transmural disease activity in patients with Crohn’s disease: current status and future perspectives. Therap Adv Gastroenterol 2021;14:1736248211066672.
9. Turner D, Ricciuto A, Lewis A, et al.; International Organization for the Study of IBD, STRIDE-H: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease [STRIDE] Initiative of the International Organization for the Study of IBD [IOIBD]: Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570–83.
10. Fitch K, Aguilar S, Burnand M, LaCelle B. The RAND/UCLA Appropriateness Method User’s Manual. Santa Monica, CA: Rand; 2001.
11. Veritas Health Innovation. Cowdence Systematic Review Software. 2019. www.covidence.org. Accessed April 2019.
12. Bots S, Nyulund K, Löwenberg M, Geczy K, Gilja OH, D’Haens G. Ultrasound for assessing disease activity in IBD patients: a systematic review of activity scores. J Crohns Colitis 2018;12:920–9.
13. Whiting PF, Rutjes AW, Westwood ME, et al.; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
14. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture [REDCap] – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.
15. Harris PA, Taylor R, Minor BL, et al.; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208.
16. Paredes JM, Moreno N, Latorre P, et al. Clinical impact of sonographic transmural healing after anti-TNF antibody treatment in patients with Crohn’s disease. Dig Dis Sci 2019;64:2600–6.
17. Paredes JM, Ripollés T, Cortés X, et al. Abdominal sonographic changes after antibody to tumor necrosis factor [anti-TNF] alpha therapy in Crohn’s disease. Dig Dis Sci 2010;55:404–10.
18. Castiglione F, Testa A, Rea M, et al. Transmural healing evaluated by bowel sonography in patients with Crohn’s disease on maintenance treatment with biologics. Inflamm Bowel Dis 2013;19:1926–34.
19. Castiglione F, Mainenti P, Testa A, et al. Cross-sectional evaluation of transmural healing in patients with Crohn’s disease on maintenance treatment with anti-TNF alpha agents. Dig Liver Dis 2017;49:484–9.
20. Kucharzik T, Wirtz BM, Helwig U, et al.; TRUST study group. Use of intestinal ultrasound to monitor Crohn’s disease activity. Clin Gastroenterol Hepatol 2017;15:533–42.e2.
21. Ripollés T, Paredes JM, Martínez-Pérez MJ, et al. Ultrasonographic changes at 12 weeks of anti-TNF drugs predict 1-year sonographic response and clinical outcome in Crohn’s disease: a multicenter study. Inflamm Bowel Dis 2016;22:2465–73.
22. Ripollés T, Martínez MJ, Barrachina MM. Crohn’s disease and color Doppler sonography: response to treatment and its relationship with long-term prognosis. J Clin Ultrasound 2008;36:267–72.
23. Dubbins PA. Ultrasound demonstration of bowel wall thickness in inflammatory bowel disease. Clin Radiol 1984;35:227–31.
24. Onali S, Calabrese E, Petruzziello C, et al. Endoscopic vs ultrasonographic findings related to Crohn’s disease recurrence: a prospective longitudinal study at 3 years. J Crohns Colitis 2010;4:139–28.
25. Moreno N, Ripollés T, Paredes JM, et al. Usefulness of abdominal ultrasound in the analysis of endoscopic activity in patients with Crohn’s disease: changes following treatment with immunomodulators and/or anti-TNF antibodies. J Crohns Colitis 2014;8:1079–87.
26. Orlando S, Coletta M, Fraquelli M, et al. Ultrasound elasticity imaging predicts therapeutic outcome in patients with Crohn’s disease treated with anti-tumor necrosis factor antibodies. Dig Liver Dis 2017;49:98–105.
27. Socaciu M, Coabarau L, Diaconu B, Hagiu C, Seicean A, Badea R. Non-invasive assessment of inflammation and treatment response in patients with Crohn’s disease and ulcerative colitis using contrast-enhanced ultrasonography quantification. J Gastrointestin Liver Dis 2015;24:657–65.
28. Goertzs RS, Klett D, Wildner D, Atreya R, Neurath MF, Strobel D. Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study. Acta Radiol 2018;59:1149–56.
29. Quaia E, Gennari AG, Cova MA. Early predictors of the long-term response to therapy in patients with Crohn disease derived from a time-intensity curve analysis after microbubble contrast agent injection. J Ultrasound Med 2019;38:947–58.
30. Savick F, Nyulund K, Hauksen T, Ødegaard S, Gilja OH. Bowel perfusion measured with dynamic contrast-enhanced ultrasound predicts treatment outcome in patients with Crohn’s disease. Inflamm Bowel Dis 2014;20:2629–37.
31. Chen JM, He LW, Yan T, et al. Oral exclusive enteral nutrition induces mucosal and transmural healing in patients with Crohn’s disease. Gastroenterol Rep [Oxf] 2019;7:176–84.
32. Hoffmann P, Krisam J, Wehling C, et al. Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease. World J Gastroenterol 2019;25:4481–92.
33. Zorzì F, Ghosh S, Chiaramonte C, et al. Response assessed by ultrasonography as target of biological treatment for Crohn’s Disease. Clin Gastroenterol Hepatol 2020;18:2030–7.
34. Calabrese E, Rispo A, Zorzi F, et al. Ultrasoundography tight control and monitoring in Crohn’s disease during different biological therapies: a multicenter study. Clin Gastroenterol Hepatol 2021. Doi: 10.1016/j.cgh.2021.01.030.

35. Hoffmann T, Fusco S, Blumenstock G, Sadik S, Malek NP, Froehlich E. Evaluation of bowel wall thickness by ultrasound as early diagnostic tool for therapeutic response in Crohn’s disease patients treated with ustekinumab. Z Gastroenterol 2020. Doi: 10.1055/a-1283-6530.

36. Ma L, Li W, Zhuang N, et al. Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn’s disease. Therap Adv Gastroenterol 2021;14:17562848211016259.

37. Helwig U, Fischer I, Hammer L, et al. Transmural response and transmural healing defined by intestinal ultrasound—new potential therapeutic target? J Crohns Colitis 2022;16:57–67.

38. Jessen B, Rodriguez-Sillke Y, Sonnenberg E, et al. Level of tumor necrosis factor produced by stimulated blood mononuclear cells can be used to predict response of patients with inflammatory bowel diseases to infliximab. Clin Gastroenterol Hepatol 2021;19:721–31.e1.

39. Parente F, Molteni M, Marino B, et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. Am J Gastroenterol 2010;105:1150–7.

40. Maaser C, Petersen F, Helwig U, et al.; German IBD Study Group and the TRUSTandUC Study Group. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUSTandUC study. Gut 2020;69:1629–36.

41. Maconi G, Ardizzzone S, Parente F, Bianchi Porro G. Ultrasoundography in the evaluation of extension, activity, and follow-up of ulcerative colitis. Scand J Gastroenterol 1999;34:1103–7.

42. Yoshida A, Kobayashi K, Ieno E, et al. Possible role of early transabdominal ultrasound in patients undergoing cytophagy for active ulcerative colitis. Intern Med 2011;50:11–5.

43. Hearn R, Su H, Taylor K, et al. The value of gastrointestinal ultrasound in predicting sonographic remission to vedolizumab: A step towards individualized biological therapy of inflammatory bowel disease [abstract]. J Gastroenterol Hepatol 2019;34:157–8.

44. Maaser C, Petersen F, Helwig U, et al. Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUSTandUC [abstract]. J Crohns Colitis 2019;13:S063-4.

45. Arienti V, Campieri M, Boriani L, et al. Management of severe ulcerative colitis with the help of high resolution ultrasonography. Am J Gastroenterol 1996;91:2163–9.

46. de Voogd F, Van Wassenaar E, Mookhoek A, et al. Decrease in bowel wall thickness at intestinal ultrasound accurately detects early endoscopic remission and improvement in ulcerative colitis patients on tofacitinib: a longitudinal prospective cohort study [abstract]. J Crohns Colitis 2021;15:S315–7.

47. Kucharcz T, Helwig U, Seibold F, et al. Improvement of intestinal ultrasound parameters within 12 weeks after treatment induction in CD and UC patients—first interim analysis of the trust beyond study [abstract]. United Eur Gastroenterol J 2020;8:356.

48. Maaser C, Helwig U, Fischer I, Rath S, Kolterer S, Kucharcz T. Patient-Reported Outcomes [PRO-2] and intestinal ultrasound in ulcerative colitis patients—subanalysis of the TRUSTandUC study cohort [abstract]. Gastroenterology 2020;158:694.

49. Nylund K, Maconi G, Hollerwegger A, et al. EFSUMB Recommendations and Guidelines for Gastrointestinal Ultrasound. Ultraschall Med 2017;38:e1–e15.

50. Nylund K, Hausken T, Ødegaard S, Eide GE, Gilja OH. Gastrointestinal wall thickness measured with transabdominal ultrasonography and its relationship to demographic factors in healthy subjects. Ultraschall Med 2012;33:E225–32.

51. Zink F, Kratzer W, Schmidt S, et al. Comparison of two high-end ultrasound systems for contrast-enhanced ultrasound quantification of mural microvascularity in Crohn’s Disease. Ultraschall Med 2016;37:74–81.

52. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2014;12:978–85.

53. Vasudevan A, Gibson PR, van Langenbergh DR. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017;23:6385–402.

54. Ordás I, Rimola J, Rodríguez S, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology 2014;146:374–82.e1.

55. Scarrillo L, Maniscalco V, Paci M, et al. Bowel ultrasound scan predicts corticosteroid failure in children with acute severe colitis. J Pediatr Gastroenterol Nutr 2020;71:46–51.

56. Dillman JR, Dehkhordy SF, Smith EA, et al. Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy. Pediatr Radiol 2017;47:924–34.

57. Kucharcz T, Wilkens R, Maconi G, et al. Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy [abstract]. J Crohns Colitis 2020;14:5046–8.

58. Kucharcz T, Wilkens R, Maconi G, et al. Intestinal ultrasound response and transmural healing after 48 weeks of treatment with ustekinumab in Crohn’s disease: STARDUST Trial sub-study [abstract]. United Eur Gastroenterol J 2020;8:1258–75.

59. Civitelli F, Nuti F, Oliva S, et al. Looking beyond mucosal healing: effect of biologic therapy on transmural healing in pediatric Crohn’s Disease. Inflamm Bowel Dis 2016;22:2418–24.

60. Moreno Sánchez N, Paredes JM, Rippollés T, et al. Treatment of abdominal fistulas in Crohn’s disease and monitoring with abdominal ultrasonography. Rev Esp Enferm Dig 2021;113:240–5.

61. Choi J, Phan R, Dubinsky M, Rosenberg H. Use of small bowel ultrasound to predict response to infliximab induction [abstract]. Pediatr Radiol 2018;48:S80.

62. Novak KL, Nylund K, Maaser C, et al. Expert consensus on optimal acquisition and development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: a reliability and inter-rater variability study on intestinal ultrasonography in Crohn’s Disease. J Crohns Colitis 2020;15:609–16.

63. Novak KL, Kaplan GG, Panaccione R, et al. A simple ultrasound score for the accurate detection of inflammatory activity in Crohn’s Disease. Inflamm Bowel Dis 2017;23:2001–10.

64. Savvik F, Eriksen R, Eide GE, Gilja OH, Nylund K. Development and validation of a simple ultrasound score for Crohn’s Disease. J Crohns Colitis 2021;15:115–24.

65. Kumihoro K, Hata J, Haruma K, Manabe N, Tanaka S, Chayama K. Sonographic detection of longitudinal ulcers in Crohn disease. Scand J Gastroenterol 2004;39:322–6.

66. Rippollés T, Pora J, Suarez Ferrer C, Martinez-Pérez MJ, Martin-Algíbez A, de Las Heras Paez B. Evaluation of Crohn’s disease activity: development of an ultrasound score in a multicenter study. Inflamm Bowel Dis 2021;27:145–54.

67. Bots S, Nylund K, Löwenberg M, Gece K, D’Haens G. Intestinal ultrasound to assess disease activity in ulcerative colitis: development of a novel UC-Ultrasound index. J Crohns Colitis 2021;15:877–8.

68. De Voogd F, Wilkens R, Gece K, et al. A reliability study: strong inter-observer agreement of an expert panel for intestinal ultrasound in ulcerative colitis. J Crohns Colitis 2021;15:1284–90.

69. Ordás I, Rimola J, Alfaro I, et al. Development and validation of a simplified magnetic resonance index of activity for Crohn’s Disease. Gastroenterology 2019;157:432–9.e1.

70. Liu C, Ding SS, Zhang K, et al. Correlation between ultrasound consolidated score and simple endoscopic score for determining the activity of Crohn’s disease. Br J Radiol 2020;93:20190614.

71. Marin AM, Calapod OP, Moldoveanu AC, Tribus LC, Fierbințe-Braticevic C. Non-invasive ultrasonographic score for assessment of the severity of inflammatory bowel disease. Ultrasound Med Biol 2021;47:932–40.
72. Ma H, Isaac DM, Petrova A, et al. Validation of a modified simple ultrasound activity score for children with Crohn’s disease [abstract]. In: Proceedings of the 16th ECCO Congress; July 2-3 and 8-10 2021; virtual.

73. Van Wassenaer E, Bennenga MA, Koot BGP, et al. The development of the PCD-US: The Pediatric Crohn’s Disease intestinal Ultrasound Score. J Pediatr Gastroenterol Nutr 2021;72:43–48.

74. Allocca M, Filippi E, Costantino A, et al. Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. United European Gastroenterol J 2021;9:38–42.

75. Zhang M, Zhang H, Zhu Q, et al. Bowel ultrasound enhances predictive value based on clinical indicators: a scoring system for moderate-to-severe endoscopic activities in patients with ulcerative colitis. Therap Adv Gastroenterol 2021;14:1756284821103050.

76. Halasz J, Lu C, Kaplan G, et al. 12-week ultrasound response to treatment, used as a predictor of response at 6 months in Crohn’s disease: A prospective cohort study [abstract]. J Crohns Colitis 2018;12:S384.

77. Di Fluri G, Ceccarelli L, Ricchiuti A, et al. Prevalence and clinical significance of defects on MDCT enterography in the assessment of transmural activity and fibrosis in Crohn’s disease. J Crohns Colitis 2018;12:S385.

78. Wilkens R, Hagemann-Madsen RH, Peters DA, et al. Validity of contrast-enhanced ultrasonography and dynamic contrast-enhanced MR enterography in the assessment of transmural activity and fibrosis in Crohn’s disease. J Crohns Colitis 2018;12:48–56.

79. McAlindon ME, Whitehead K, Sheean P, et al. Serum CRP, tissue IgG, and urine IL-18 as markers of intestinal inflammation in CD: a prospective study. Gut 2021;70:908–21.e6.

80. Haber HP, Busch A, Ziebarth R, Stern M. Bowel wall thickness measured by ultrasound as a marker of Crohn’s disease activity in children [research letter]. Lancet 2000;355:1239–40.

81. Geyl S, Guillo L, Laurent V, et al. Validation of a modified simple ultrasound scoring in clinical trials for luminal Crohn’s disease. Aliment Pharmacol Ther 2021;53:873–86.

82. Yu H, Zhang X, Wang J, et al. Correlation of ultrasound appearances with clinical and laboratory features in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2021;19:908–21.e6.

83. Peyrin-Biroulet L, Pan JH, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol 2016;14:348–54.e17.

84. Peyrin-Biroulet L, Reimisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 2014;63:88–95.